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Summary 
In recent years, many “new psychoactive substances” (NPS), such as amphetamine and 
synthetic cathinone derivatives, have dramatically appeared on the illegal market, and the abuse 
of these drugs is now a global crisis. The mechanisms of cytotoxicity associated with NPS are 
still unclarified. The aims of this thesis were to comprehensively evaluate the mechanisms of 
NPS-induced myotoxicity, hepatotoxicity and neurotoxicity in vitro, and as well as to assess 
the role of hyperthermia on methcathinone-induced neurotoxicity. Therefore, we treated human 
hepatoma HepG2 cells, mouse muscle C2C12 cells, and human neuroblastoma SH-SY5Y cells 
with amphetamines and synthetic cathinones at concentrations from 50-2000 µM. 
In the first paper, we focused on the toxicological effects in C2C12 cells of the 
following synthetic cathinones: 3,4-methylenedioxymethcathinone (methylone), 
4-methylmethcathinone (4-MMC, mephedrone), 3-methylmethcathinone (3-MMC), 
methylenedioxypyrovalerone (MDPV), α-pyrrolidinopentiophenone (α-PVP), and 
naphthylpyrovalerone (naphyrone). All the investigated synthetic cathinones showed a 
concentration-dependent impairment of the cell membrane integrity, a drop in intracellular 
adenosine triphosphate (ATP) content, and an increase of mitochondrial superoxide 
concentrations. α-PVP and naphyrone impaired basal and maximal cellular respiration and 
inhibited the activities of complex I and II of the electron transport chain (ETC). These results 
indicated mitochondrial dysfunction associated with these drugs. In conclusion, α-PVP and 
naphyrone showed mitochondrial toxicity after 24 h exposure. In comparison, the cytotoxic 
effects of methylone, 4-MMC (mephedrone), 3-MMC and MDPV were related to an 
impairment of glycolysis rather than inhibition of mitochondrial pathways. 
The goal of the second paper was to investigate the pharmacological profile and the 
potential hepatotoxicity of para-halogenated amphetamines and cathinones in vitro. We 
determined the pharmacological profile in transporter-transfected human embryonic kidney 
293 cells (HEK 293). Amphetamine, 4-fluoroamphetamine (4-FA), 4-chloroamphetamine 
(PCA), methcathinone (MC), 4-fluoromethcathinone (4-FMC) and 4-chloromethcathinone 
(4-CMC) inhibited the norepinephrine transporter (NET) and the dopamine transporter (DAT). 
Moreover, the inhibition of these compounds on the dopamine versus the serotonin transporter, 
showed selectivity in their activity, which decreased together with the increasing size of the 
para-substituents, resulting in an inhibition of the serotonin uptake. Concerning the assessment 
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of hepatocellular toxicity, we found that all substances induced membrane toxicity, depletion 
of the intracellular ATP content and formation of reactive oxygen species (ROS) in HepG2 
cells. The decrease in the ATP content was at a lower concentration than the damage of the cell 
membrane integrity, which suggests mitochondrial toxicity. Furthermore, amphetamines and 
4-CMC impaired the mitochondrial respiratory chain, confirming their nature as mitochondrial 
toxicants. Finally, both 4-FA and 4-CMC induced apoptosis and necrosis in HepG2 cells. 
Taken together, para-halogenation of amphetamines and cathinones increase the risk for 
serotonergic neurotoxicity, which may induce hyperthermia in vivo. The toxicity rank of the 
substitutes was the following: chloride > fluoride > hydrogen. 
The purpose of the third study was to characterize the mechanisms of neurotoxicity of 
amphetamine, 4-FA, PCA, methcathinone (MC), 4-FMC and 4-CMC. 4-FA, PCA and 4-CMC 
strongly impaired membrane integrity, depleted ATP intracellular content and decreased the 
mitochondrial membrane potential of undifferentiated and differentiated neuronal SH-SY5Y 
cells, indicating mitochondrial toxicity. Moreover, PCA and 4-CMC inhibited the function of 
the ETC, increased ROS and induced apoptosis for both cell types. Besides that, caspase 3 and 
9 were activated after 4-CMC exposure. In conclusion, PCA and 4-CMC impaired the function 
of mitochondria and induced apoptosis in undifferentiated and differentiated SH-SY5Y cells, 
while 4-FA depleted ATP content, increased ROS formation, and decreased mitochondrial 
membrane potential in undifferentiated SH-SY5Y cells. This study further supported the 
toxicity rank of para-halogenated amphetamines and cathinones (Cl > F > H). 
In the last study, we investigated the effects of hyperthermia (40.5 °C) on the 
neurotoxicity of MC, 4-MMC and 4-CMC in SH-SY5Y cells. We found that 4-MMC and 
4-CMC caused cell membrane damage, decreased intracellular ATP content, impaired the 
function of ETC, and increased ROS levels at both thermic conditions. At the hyperthermic 
condition (40.5 °C), SH-SY5Y cells exposed to test drugs were more sensitive than at the 
normothermic condition (37 °C). MC also induced an increase of ROS and inhibited ETC, 
however only at the hyperthermic condition. Moreover, hyperthermia reduced drug-induced 
apoptosis by promoting the expression of the 70 kilodalton heat shock proteins (Hsp70), but 
was associated with late autophagy and cell death. In conclusion, hyperthermic conditions 
increased the neurotoxic properties of methcathinones due to enhanced impairment of 
mitochondrial function and induced late autophagy and cell death when early protective 
measures were overwhelmed.  
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1. Psychoactive Drugs 
Psychoactive drug is a generic term referring to some chemical substance that can act 
on the function of the nervous system and lead to psychological effects such as changes in 
perception, mood, feelings, awareness and/or behaviour. Psychotropic drugs are mainly 
classified into three groups [1]: 
• Stimulants: substances that can excite the body’s central nervous system (CNS) and 
can cause anxiety, psychosis, paranoia, hyperthermia, depression, heart failure, stroke, 
seizures and even death. Common stimulants include nicotine, amphetamines, cocaine, 
ritalin, methamphetamine, ecstasy, caffeine [2]. 
• Depressants: substances that can slow down the CNS. The abuse of depressants can 
increase sluggish thinking, induce sedation and sleep and are associated with 
dependence after repetitive ingestion with withdrawal symptoms. Examples of 
depressants include benzodiazepines such as flunitrazepam, diazepam and midazolam, 
the benzodiazepine-like Z-drugs such as zolpidem and the barbiturates 
benzodiazepines [3]. 
• Hallucinogens: substances that can distort the communication within different areas 
of the brain. Users report some immediate impact as rapidly shifting emotions, 
flashbacks, distorted cognition, paranoia, hallucinations, anxiety, nausea. Examples of 
hallucinogens include LSD, mescaline, “magic mushrooms”, ecstasy, cathinones, and 
cannabis [4, 5].	
1.1. New Psychoactive Substances (NPS) 
New psychoactive substances (NPS) are a wide variety of psychoactive compounds 
which are not controlled by the 1961 Convention on Narcotic Drugs or the 1971 Convention 
of Psychotropic Substances [6]. They are also known as “legal highs”, “bath salts”, “plant 
food”, “herbal highs”, “party pills” or “research chemicals”. Since the 2000s, a large number 
of NPS has begun to appear on the illicit market and over the internet for recreational use. 
The drug manufacturers create novel compounds to circumvent the ban of drugs in some 
countries, in order to stay ahead of the law [7]. However, NPS are not innocuous recreational 
substances, they can be as harmful as illicit drugs to users. A large part of NPS is represented 
Introduction	
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by derivatives of amphetamine and synthetic cathinones [6]. The structures of some 
amphetamine and cathinone derivatives are shown in Figure 1. 
 
Figure 1. Chemical structure of some amphetamines and synthetic cathinones. 
1.2. Halogenation	
Halogenation is an easy and effective method for modification of known compounds 
in order to change their solubility and their pharmacological properties. Chlorination and 
bromination are the predominant modification, while fluorination and iodination are 
performed more rarely [8]. The introduction of halogenated substituents into many natural 
compounds can profoundly affect their biological activity [9], and can modify membrane 
binding and cell permeation [10]. 
Halogenation is also an effective tool to create NPS, since many common 
psychoactive drugs have been banned in many countries. For instance, para-halogenated 
amphetamines and methcathinones, 4-FA, PCA, 4-FMC and 4-CMC, have recently appeared 
on the illegal drug market [11-15]. As mentioned above, halogenation can change the 
pharmacological and toxicological profile of psychoactive drugs. PCA has an increased 
serotonergic toxicity when compared to amphetamine in vitro [16-18]. In a microdialysis 
study of the nucleus accumbens in rats, para-halogenated methcathinones (-F, -Cl or -Br) 
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increased dopamine (DA) and 5-hydroxytryptamine (5-HT) release with different potencies 
compared to methcathinone [19]. 
1.3. Amphetamines 
Amphetamines form a family of structurally similar drugs [20], including natural 
alkaloids and chemically synthesized derivatives [21]. Natural amphetamines have been used 
as plant products for more than thousand-years and extracted from various genus of the plant 
Ephedra and from the tree Catha edulisor [21]. Since Lazar Edeleanu produced the first 
synthetic amphetamine in 1887 [22], many chemically synthesized amphetamine derivatives 
have appeared, for instance methamphetamine (METH) and 
3,4-methylenedioxymethamphetamine (MDMA, ecstasy) [21, 23]. The structural definition 
of amphetamines was reported by J.H. Biel and B.A. Bopp in 1978 [24]: (1) an unsubstituted 
phenyl ring, (2) a two-carbon side chain between the phenyl ring and nitrogen, (3) an 
α-methyl group, and (4) a primary amino group [25] (Figure 2). 
 
Figure 2. The generic structure for amphetamines. 
General pharmacological properties of amphetamines are shown in Figure 3. 
Amphetamines predominantly enter into the cell cytoplasm through neuronal monoamine 
transporters [26]. Amphetamines can affect the peripheral and central human nervous system 
through their interaction with the presynaptic monoamine transporters of dopamine (DAT), 
serotonin (SERT) and noradrenaline (NAT) [20]. Moreover, amphetamines act as 
competitive substrates for transporters in the uptake of biogenic amines such dopamine (DA), 
norepinephrine (NE), and serotonin (5-HT) [27]. Furthermore, amphetamines have different 
affinity for DAT, NAT and SERT [20]. The selectivity of amphetamines also corresponds to 
the specific neurotoxic effects of these drugs [20]. They can bind to intracellular vesicular 
monoamine transporter 2 (VMAT 2), thereby reducing vesicular monoamine storage. 
Amphetamines can also inhibit monoamine oxidase (MAO)-mediated monoamine 
breakdown, thereby increasing cytoplasmic monoamine concentrations [28]. Eventually,	
excessive extracellular noradrenaline, dopamine and serotonin lead to acute toxicity	[29]. An 
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obvious clinical manifestation is the α- and β-adrenergic receptor-mediated sympathomimetic 
toxidrome [29]. 
 
Figure 3. Mechanism of action of amphetamines on synaptic terminal of neurons	[30]. 	
Amphetamine (Figure 4) was first synthesized in 1887, and initially it has primarily 
been used as a stimulant [31]. Since 1930, amphetamine was being prescribed to treat 
narcolepsy and obesity [31, 32]. It was also noted in the 1930s that amphetamine is able to 
cross the blood brain barrier (BBB) and induce a wide range of behavioral changes, such as 
euphoria and pleasurable effects [31]. These effects resulted in a widespread prescription and 
also in drug abuse [31]. After the addictive potential of amphetamine had been observed and 
described, amphetamine was classified under the Convention on Psychotropic Substances as 
a Schedule II drug in the US and internationally [33]. 
 
Figure 4. Chemical structure of amphetamine.	
MDMA (3,4-methylenedioxymethamphetamine, Figure 5), is an 
amphetamine-derivative and was initially synthesized as a member of new haemostatic 
substances in 1912 by Merck [23]. In the 1970s, MDMA was used as medicine to enhance 
Amphetamine
NH2
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the effect of psychotherapy, then, it became popular as recreational drug for decades [34]. 
Although MDMA is not a novel psychoactive substance, it still occupies one of the largest 
shares of recreational use. MDMA is a stimulant and enhances sociability [35], such as 
emotional empathy, trust and extroversion [36, 37]. MDMA has a significant higher affinity 
for 5-HTT and NAT over DAT, due mainly to the addition of the 3,4-methylenedioxy group 
to the phenyl ring	[38]. For this reason, MDMA is considered a primarily serotonergic drug, 
with less sympathomimetic effects than amphetamine at low doses	[29]. The low activity for 
DAT explains its low or lacking addictive potential, which is different from amphetamine. 
 
Figure 5. Chemical structure of MDMA	
4-Fluoroamphetamine (4-FA, Figure 6) is a para-substituted amphetamine, which 
has been synthesized in the 1940s [39]. It was first used as a recreational drug in 2003 [40]. 
In a survey among the users, 4-FA shares comparable subjective effects with amphetamine 
and MDMA [41]. In animal studies, 4-FA can induce the release of NE, DA and 5-HT and 
inhibit their reuptake in the brain [41-44]. Different from other para-halogenated compounds, 
4-FA does not deplete the neuronal 5-HT in the brain of rats [45]. This may reflect the fact 
that 4-FA, due to the fluoride in the p-position, is metabolized differently compared to 
amphetamine. 
 
Figure 6. Chemical structure of 4-FA.	
4-Chloroamphetamine (PCA, Figure 7) is another para-substituted derivative of 
amphetamine, known as depletor of brain serotonin [46], since it selectively toxic on 
serotonergic neurons in animal studies [16]. The clinical effects of PCA are considered to be 
similar to MDMA, however, it shows a higher neurotoxicity due to the effects of its 
H
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O
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metabolites [16]. In addition to acute reversible neurotoxicity, PCA has as well long-term 
effects, including tryptophan hydroxylase inactivation and neuronal destruction [16]. 
 
Figure 7. Chemical structure of PCA 
1.4. Synthetic Cathinones 
Cathinone (Figure 8A) is an alkaloid that has been first isolated from the fresh leaves 
of khat shrub (Catha edulis) in 1975. Cathinones are β-keto amphetamine derivatives [47], 
which psychostimulant effects [48]. Many experiments have demonstrated that cathinone has 
a pharmacological profile on the CNS and sympathomimetic effects close to amphetamine 
[49]. However, isolated cathinone degrades rapidly. For clinical use, a growing number of 
synthetic cathinone derivatives have been synthesized, such as bupropion, which was 
introduced as an antidepressant in 1985. 
Synthetic cathinones (Figure 8B), which were designated as “legal highs”, have 
recently emerged and rapidly grown into the NPS scene [50]. Nowadays, nearly more than 
one hundred different synthetic cathinones were detected by the European Union Early 
Warning System from 2005 to 2017 [51, 52].  
  
Figure 8. Chemical structure of (A) cathinone and general structure of (B) synthetic cathinones [50]. 
In vitro studies of synthetic cathinones have shown that they can penetrate the BBB 
easily [53]. Increasing concentration of catecholamines into the inter-synaptic space can 
stimulate the CNS and sympathetic nerve system, and their effects are usually stronger than 
for amphetamines, despite their structures are similar [54]. Similar to amphetamine, synthetic 
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cathinones can inhibit some monoamine transporters, including the dopamine transporter 
(DAT), the noradrenaline transporter (NAT), and the serotonin transporter (SERT) [54]. 
According to the mechanisms of action, synthetic cathinones can be classified into three 
groups [53, 54]: 
• Cocaine-MDMA-mixed cathinone group. This group can non-selectively inhibit 
monoamine uptake (similar to cocaine) and promote serotonin liberation (similar to 
MDMA) (e.g. 4-MMC, methylone). 
• Methamphetamine-like cathinone group. This group can preferentially inhibit the 
reuptake of catecholamines and induce the release of DA (e.g. methcathinone, 4-FMC 
and 4-CMC). 
• Pyrovalerone-cathinone group. Members of this group are potent and selective 
inhibitors of the DA and NA transporter (e.g. MDPV and α-PVP). 
Methcathinone (MC, Figure 9), commonly known as ephedrone, is a methyl 
derivative of cathinone [55]. It was first developed during the processes of synthesis of 
ephedrine in Germany and France in the early 1920s [56]. During the 1930s and 1940s, it was 
used as an antidepressant in the Soviet Union [57]. Between the 1950s and the 1960s, 
methcathinone was studied as a potential appetite suppressant, but its strong addictive 
potential was gradually revealed and the clinical applications were stopped [58]. During the 
1970s and 1980s, methcathinone had a widespread recreational use under the name of “Jeff” 
in the USSR [59]. Subsequently, it appeared in the USA in the early 1990s, where its 
popularity increased rapidly [59]. In 1993, it was added to the Federal Controlled Substances 
Act [60]. Finally, in 1994, it was included under the Schedule I of the UN Convention on 
Psychotropic Substances [59]. Methcathinone has a similar pharmacological mechanisms as 
amphetamine with a comparable monoamine transporter inhibition profile	[53]. 
 
Figure 9. Chemical structure of methcathinone.	
O
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N
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4-Methylmethcathinone (mephedrone, 4-MMC, Figure 10) was first reported by 
Saem de Burnaga Sanchez in 1929 [61]. 4-MMC has remained in obscurity until 2003, when 
clandestine chemists rediscovered it and communicated it online [62]. It became widely 
abused as an alternative to MDMA in the subsequent decade, due to its low price and low 
harm potential [63, 64]. Since more and more reports of hospital admissions and overdose 
deaths appeared with time, mephedrone has been classified as a Class B substance under the 
Misuse of Drugs Act in 2010 [65]. Following that, it was banned by all European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) member states in 2010 and by the USA in 
2011 [66, 67]. 
 
Figure 10. Chemical structure of 4-MMC	
3-Methylmethcathinone (3-MMC, Figure 11) is a synthetic cathinone and a 
structural isomer of mephedrone, which was reported in 2012 by the Swedish Poisons 
Information Centre in 2012 [68]. It is one of the most popular NPS around the world [69]. 
Due to its sweet liquorice-like taste, it was also called as sladoled, ice cream [70, 71]. It is a 
substitute of mephedrone, with similar psychostimulant properties and weaker toxicological 
effects than its mephedrone [69, 71-73]. 
 
Figure 11. Chemical structure of 3-MMC	
Methylone (3,4-methylenedioxymethcathinone, MDMC, βk-MDMA, Figure 12), is a 
cathinone derivative and an analogue of MDMA. It was first developed by Peyton Jacob III 
and Alexander Shulgin, and patented as a potential antidepressant in 1996 [74, 75]. At around 
2004, methylone began to emerge online under the name “Explosion” and was then abused in 
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several countries, such as Japan, USA, and also in Europe [76, 77]. Since 2007, it became 
illegal in Sweden, and then it has also been banned in the UK and France in 2010 and 2012, 
respectively [75]. Compared to MDMA, methylone has subtle differences on the effects of 
recreational use [78], with which it shares similar risks and adverse effects [75, 79]. The 
pharmacological profile is similar to 4-MMC [53]. 
 
Figure 12. Chemical structure of methylone	
Methylenedioxypyrovalerone (MDPV, Figure 13) is a stimulant and member of the 
cathinone class. It was first synthesized by Boehringer Ingelheim in 1969 [80]. Until 2004, 
MDPV was reported as a new designer drug and then sold as the major component of “bath 
salts” [81, 82]. Since 2010, MDPV became a controlled substance in the UK, Australia, and 
in some European countries [83]. Moreover, it is controlled in the USA as Schedule I 
controlled substance (2011) [84]. Structurally, MDPV is similar to MDMA. They both 
contain a 3,4-methylenedioxy ring and the phenyl group, while MDPV presents a pyrrolidine 
ring. MDPV is a blocker of DAT and NET [53, 85, 86]. Due to the pyrrolidine ring, the 
pharmacological properties of MDPV are distinct from other synthetic cathinones [82, 87]. In 
this regard, MDPV is pharmacologically much similar to cocaine rather than to cathinone [82, 
87]. 
 
Figure 13. Chemical structure of MDPV	
α-Pyrrolidinopentiophenone (α-PVP, “gravel” or “flakka”, Figure 14) is a 
pyrrolidine-type cathinone derivative and known as a component of “bath salts” [88]. It was 
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developed by Boehringer Ingelheim in the 1960s as CNS stimulant and pressor agent [88]. 
Since α-PVP has been reported to cause human fatalities, it was placed by the US DEA under 
Schedule I in a temporary scheduling action in 2014 [89-91]. 
 
Figure 14. Chemical structure of α-PVP 
Naphyrone (Figure 15), which is also well known as NRG-1 or O-2482, is derived 
from pyrovalerone [92]. It was first synthesized in 1964 and then sold as a triple reuptake 
inhibitor with stimulant effects [93]. To date, naphyrone is scheduled as Class B drug in the 
UK since 2010 [94]. Due to its structure, naphyrone has higher lipophilicity than other 
synthetic cathinones, and it can easier permeate brain increasing its exposure in vivo [95]. 
Currently, there are little data about the toxicology of naphyrone, since is usually used in 
mixture with other cathinones [96]. The monoamine uptake transporter inhibition profile of 
naphyrone is very similar to the one of cocaine [53]. Moreover, naphyrone is not a 
monoamine releaser [53]. 
 
Figure 15. Chemical structure of naphyrone. 
4-Fluoromethcathinone (4-FMC, flephedrone, Figure 16) was first reported in 1952 
as a potentially antibacterial, antithyroidal and bacteriostatic medicine [97, 98]. Since 2010, 
many countries have listed 4-FMC as illegal substance [99]. It is also listed as Schedule I 
controlled substance in the US	[91]. 4-FMC belongs to “methamphetamine-like cathinones” 
O
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group, and it has similar pharmacological profile with 4-FA [43]. 4-FMC can inhibit DAT 
but not 5-HTT, it is also a potent releaser of DA but not of 5-HT [43]. 
 
Figure 16. Chemical structure of 4-FMC	
4-Chloromethcathinone (4-CMC, Figure 17) is a chlorine-substituted cathinone, 
which appeared in the internet as a designer drug since 2014 [14]. It is strictly controlled in 
many countries, such as Germany, China and the USA [100]. There is little data about its 
pharmacokinetic, pharmacological and toxicological effects [101]. It is often sold with 
MDMA or even as a fake MDMA [11]. The effects on the users depend on the route of 
administration: oral ingestion leads to a euphoric effect, while snorting can increase 
concentration and self-confidence [101]. 
 
Figure 17. Chemical structure of 4-CMC 
2. Toxicology 
2.1. Clinical Effects 
Amphetamine abuse leads to a wide range of clinical manifestations. Clinical effects 
of acute and chronic use of amphetamines and synthetic cathinones are summarized in Table 
2 [29, 79]. 
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Table 2. Clinical manifestations of amphetamines and synthetic cathinones toxicity. 
  
2.1.1. Myotoxicity 
In some reports from poison control centres, users who abused amphetamines 
present increased muscle tension and increased serum levels of creatine phosphokinase (CPK) 
[102]. Long-term use of amphetamines and its analogues can cause muscle ache, increase 
muscle tension and provoke spasms [103, 104]. In vivo studies in mice have shown that the 
combination of MDMA and exercise can induce skeletal muscle toxicity and even lead to 
rhabdomyolysis	 [105]. MDMA-induced skeletal muscle toxicity may be caused by an 
increase in mitochondrial proton leakage in vivo through the expression of the uncoupling 
protein 3 (UCP3)	[106]. Users of synthetic cathinones also reported clinical effects on muscle 
such as numbness, tingling, muscular tension and cramping [79]. These drugs also elevate 
serum creatinine kinase levels and may cause rhabdomyolysis [79]. 
2.1.2. Hepatoxicity 
Overdose of amphetamines and synthetic cathinones is considered as a potential 
cause that may induce acute liver injury [107]. In some Western countries, as amphetamines 
and synthetic cathinones become more and more popular as recreational drugs, they have 
System Amphetamines Synthetic Cathinones
Cardiovascular
Tachycardia, hypertension, aortic dissection,
arrhythmias, vasospasm, acute coronary syndrome,
hypotension (late sign), acute cardiomyopathy
Palpitations, shortness of breath, chest pain
Neurologic
Agitation, paranoia, euphoria, hallucinations, bruxism,
hyperreflexia, intracerebral haemorrhage,
choreoathetoid movements, anorexia, hyperthermia,
seizures, coma
Aggressiveness, bruxism, dizziness, headache,
lightheadness, memory loss, tremor, seizures, Anger,
anxiety, auditory and visual hallucinations, depression,
dysphoria, empathy, euphoria, fatigue, formication,
increased energy, increased and decreased concentration,
loquaciousness, panic, paranoia, perceptual distortions,
restlessness
Gastrointestinal Nausea, vomiting, diarrhoea, gastrointestinal ischaemia Abdominal pain, anorexia, nausea, vomiting
Pulmonary
Non-cardiogenic pulmonary oedema/adult respiratory
distress syndrome, tachypnoea Shortness of breath
Musculoskeletal Muscle rigidity, rhabdomyolysis
Arthralgias, extremity changes—coldness,
discoloration, numbness, tingling, muscular tension and
cramping
Ophthalmologic Mydriasis, nystagmus, visual hallucinations (rarely) Blurred vision, mydriasis, nystagmus
Genitourinary Erectile dysfunction Anorgasmia, erectile dysfunction, increased libido
ENT Auditory hallucinations (rarely) Dry mouth, epistaxis, nasal pain, “nose burns”,oropharyngeal pain, tinnitus
Chronic Toxicity
Behavioural/psychiatric illness, cardiomyopathy,
cardiac valve disease, pulmonary hypertension,
vasculitis
Depression, infrequent hallucinations, impaired
inhibition (similar to alcohol), increased risk
of myocardial infarction (heart attack), psychosis in
extreme cases in the genetically predisposed
Others
Hepatitis, hyponatraemia (dilutional/syndrome
inappropriate anti diuretic hormone), acidosis,
diaphoresis,
Body odor “mephedrone stink”, diaphoresis, fever,
insomnia, nightmares, skin rash
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become one of the main causes of acute hepatitis and acute liver failure [108]. Histological 
changes in the liver after amphetamines exposure include individual cell necrosis, 
centrilobular necrosis and even massive hepatic necrosis, which may be related with acute 
hepatic failure [109-111]. Some users developed jaundice in addition to elevation of 
transaminases, which may reflect potentially fatal fulminant liver failure [112-115]. There is 
also experimental evidence for amphetamine-induced hepatotoxicity in animal studies. 
Amphetamines, especially MDMA, have been observed to cause liver necrosis in mice and 
rats	 [116, 117]. In vitro studies verified that mitochondrial dysfunction and apoptosis 
contribute to hepatotoxicity associated with amphetamines	 [118-120]. For synthetic 
cathinones, hepatotoxicity data are currently scarce. A case of acute liver failure has been 
reported after ingestion of MDPV	[121]. Moreover, MDPV and methylone have been shown 
to be toxic for rat hepatocytes, HepG2 cells and HepaRG cells, affecting mitochondrial 
function and inducing oxidative stress	[122-124]. 
2.1.3. Neurotoxicity 
The acute neurologic effects of amphetamines include positive subjective effects, 
like euphoria, increased alertness, an increased state of arousal, and increases in energy and 
ability to talk. Negative effects include anxiety, paranoia, auditory and visual hallucinations 
[125, 126]. Long-term abuse of amphetamines may impair memory, attention, and 
decision-making, and induce psychosis and aggressiveness [127]. In some in vivo studies, 
acute and high doses of amphetamines altered dopaminergic (amphetamine and 
methamphetamine) or serotonergic neurons (MDMA)	[128-131]. Some studies have shown 
that high-doses of amphetamines increased chromatolysis in medullary neurons in cats, and 
induced hemorrhage, hyperemia and glial proliferation in monkeys	 [132, 133]. Parenteral 
administration of these drugs in rats and mice can reduce the number of dopaminergic axons 
and terminals, and lead to serotonin deficits	[129]. The clinical neurologic manifestations of 
synthetic cathinones in users include agitation, aggression, altered mental status, collapse, 
confusion, dizziness, drowsiness, dystonia, headache, hyperreflexia, myoclonus, seizures, 
tremor [79]. It has been shown in in vivo studies that synthetic cathinones such as 4-MMC, 
methylone and MDPV may trigger inflammatory processes in mice brain areas, leading to 
neuronal degeneration [134]. Most synthetic cathinones can alter monoaminergic system via 
altering the transporters and receptors of DA and 5-HT [135], and can induce neuron toxicity 
via oxidative stress [135]. 
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2.2. In vitro cell models 
2.2.1. C2C12 cell line 
The C2C12 cell line (Figure 18) is an immortalized murine myoblast cell line, which 
was derived from the C2 (C3H strain) cell line [136]. The original C2 cell line was obtained 
by Yaffe and Saxel in 1977 by establishing primary cultures from the thigh leg muscle of 2-
month-old normal C3H mice	[136]. The C2C12 cells are very proliferative muscle satellite 
cells, commonly used as the standard model for skeletal or cardiac muscle [136-138]. The 
C2C12 cell line has also been used to study mechanistic biochemical pathways and to 
understand the early myogenesis [139]. Moreover, the C2C12 cell line is a useful model to 
study the cell cycle since it has a high division rate	[140]. 
.  
Figure 18. C2C12 myoblast under microscope, 100x magnification	[141]. 
2.2.2. HepG2 cell line 
Hepatic cell lines have been widely used in vitro for the studies of hepatocellular 
functions and toxicity	 [142]. In comparison to primary cultured human hepatocytes, the 
advantages of hepatic cell lines include continuous growth, unlimited lifespan, stable 
phenotype, easy availability, simple culture conditions, and standardized methods among 
laboratories. Additionally, some hepatic cell lines retain, at least in part, a differentiated adult 
phenotype. However, the expression of biotransformation activities on hepatic cell lines is 
limited, at least in HepG2 cells [143]. 
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The human hepatoma HepG2 cell line (Figure 19) was derived from the liver tissue 
biopsy of a 15 years old boy with a well-differentiated hepatocellular carcinoma	[144]. It is 
the most widely used in vitro model for polarized human hepatocytes	[144]. The HepG2 cell 
line has many liver-specific functions and also can express conjugating enzymes [143]. It 
also can secrete many major plasma proteins, such as albumin, α1-antitrypsin, 
α2-macroglobulin, plasminogen and transferrin. However, HepG2 cells do not express most 
of the relevant human liver cytochromes P450 (CYPs) [145]. Besides that, this cell line can 
be used to study the cellular trafficking and dynamics of lipids, sinusoidal membrane proteins 
and bile canaliculi in hepatocytes, which is important for human liver diseases that are 
induced by an incorrect subcellular distribution of liver cell surface proteins	[146, 147]. 
	
Figure 19. HepG2 cells under microscope, 100x magnification	[148]. 
2.2.3. SH-SY5Y cell line 
The human neuroblastoma SH-SY5Y cell line (Figure 20) was originally derived 
from the SK-N-SH cell line, which was subcloned from a bone marrow biopsy of a 4 years 
old girl with neuroblastoma	[149]. The SH-SY5Y cell line is an adrenergic and dopaminergic 
neuronal cell line that has been utilized as a model for neuroscience researches in vitro	[150]. 
The SH-SY5Y cell line is also useful in the fields of some neurological disease and disorders 
such as Parkinson’s and Alzheimer’s, and in toxicological studies	[151-153]. The advantages 
of SH-SY5Y cells are the following: 
• They are human-derived cells, which can express many human-specific proteins and 
protein isoforms. 
• They are easy to culture with low cost. 
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• They have the capacity for large-scale expansion, which can overcome the propagate-
limitation of human mature neurons. 
• They can differentiate into different neurons as needed, with adrenergic or 
dopaminergic phenotype. 
• It is a cell-line, avoiding ethical concerns of primary cell cultures [154]. 
 
Figure 20. SH-SY5Y cells under microscope, 100x magnification	[155] 
In order to obtain nearly pure human neuronlike cells, all-trans-retinoic acid 
(ATRA) and brain-derived neurotrophic factor (BDNF) in can be used to differentiate 
SH-SY5Y cells [156]. Using this method, plenty of cell with a neuronal morphology can be 
obtained (Figure 21) [156, 157]. 
 
Figure 21. Cell differentiation effects of sequential treatment of SH-SY5Y cells	 with ATRA. (a) 
Neuroblastoma cell line SH-SY5Y cells. (b) Cells incubated with ATRA. (c) Cell incubated with ATRA 
followed by BDNF, 200x magnification [157]. 
2.3. Mitochondrial Function 
Mitochondria (Figure 22) are rod-shaped organelles with a two-layer membrane, 
which are considered as the “power house” of cells. They measure only 0.5 to 1.0 microns, 
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but they can be considered the most important oxidative phosphorylation (OXPHOS) 
machinery and metabolic signaling center of cells [158]. Mitochondria have many important 
biological functions: (1) first of all they produce energy in the form of ATP, (2) they maintain 
cytosolic homeostasis of calcium ions within the compartments of the cell, (3) they 
participate in the synthesis of lipids, (4) they produce iron-sulphur clusters, (5) they build 
certain components of blood, and hormones like testosterone and estrogen, (6) they have 
functional enzymes to detoxify ammonia in the liver and to degrade fatty acids, and finally (7) 
they can regulate the process of apoptosis [159-162]. Mitochondria play therefore an 
important role in biological homeostasis of cells. Mitochondrial dysfunction can cause cell 
death, which can affect the function of organs and potentially in a variety of human diseases 
or death [163]. In toxicological studies on psychoactive drugs, mitochondria have been 
considered as the main target organs of these drugs [164]. 
 
 
Figure 22. Schematic representation of a mitochondrion. 
The most prominent role of mitochondria is to convert oxygen and nutrients into ATP, 
in fact mitochondria provide more than 90% of the ATP used by cells. ATP is the “molecular 
unit of currency” of cells since it provides the power to drive most cellular metabolic 
activities [165]. Mammalian cells produce ATP by two metabolic pathways: oxidative 
phosphorylation and glycolysis. For OXPHOS, the generation of ATP is accomplished via 
enzyme complexes the electron transport chain and the F1F0-ATPase. On the other hand, 
glycolysis is the first metabolic pathway used to extract energy when glucose is available. 
2.3.1. Mitochondrial electron transfer chain 
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The mitochondrial electron transfer chain (ETC) is located in the inner membrane of 
mitochondria and consists of complex I, complex II, complex III and complex IV	[166]. 
Complex I (NADH: ubiquinone oxidoreductase) is the largest complex and the first 
enzyme of the mitochondrial electron transport chain (ETC). It has a L-shaped architecture 
with a membrane arm and a peripheral arm. In addition to participating in the oxidative 
phosphorylation process, complex I also plays an important role in the formation of 
mitochondrial ROS and in the pathogenesis of a large number of genetic and degenerative 
disorders [167]. 
Complex II (SQR: succinate ubiquinone oxidoreductase) has four nuclear-encoded 
subunits: SDHA, SDHB, SDHC and SDHD. It lacks subunits encoded by the mitochondrial 
genome, thus it is distinguished from the other 3 complexes. Complex II is not only involved 
in the ETC but also closely related to the TCA cycle [168]. The function of complex II in 
oxidative phosphorylation has been described before the description of the succinate 
dehydrogenase (SDH) activity. Complex II contributes significantly to the TCA cycle by the 
oxidation of succinate to fumarate [169]. 
Complex III (ubiquinol: cytochrome c oxidoreductase) is considered to be another 
producer of superoxide and derived ROS besides complex I. Studies have shown that 
complex III generates superoxide at the ubiquinol oxidation center (Qo site, center P), 
suggesting that electrons are transferred from reduced cytochrome bL to oxygen via 
ubiquinone in a reverse reaction rather than through ubiquinone during a forward Q cycle 
reaction [170]. 
Complex IV (cytochrome c oxidase) is the terminal electron acceptor of the 
mitochondrial ETC, which is formed by cytochrome c oxidase (COX) embedded in the 
mitochondrial inner membrane [171]. Complex IV is a complex metalloprotein, which can 
catalyze the transfer of electrons from reduced cytochrome c to molecular oxygen [172]. In 
addition, it has proton-pumping activity that preserves the free energy released in this 
extra-energetic reaction by maintaining a transmembrane proton gradient, which is used to 
drive the synthesis of ATP or transmembrane transport [172, 173]. 
2.3.2. Oxidative Phosphorylation 
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The processes of oxidative phosphorylation are the following (Figure 23): (1) the 
tricarboxylic acid cycle (TCA) generates NADH and FADH2, which are electron donors for 
the electron transport chain. NADH and FADH2 are high-energy molecules that are shuttled 
through the ETC. NADH and FADH2 transfer energy to protein complex I and complex II, 
respectively. During this process, NADH and FADH2 will lose electrons due to oxidation. (2) 
Matrix protons (H+) are pumped into the intermembrane space by complex I, while the 
electrons are given to another membrane-bound electron carrier (ubiquinone Q). The 
complexes III and IV also repeat this proton-pumping process and accumulate protons in the 
intermembrane space, which results in a pH gradient and creates a proton-motive force. (3) 
UQH2 transfers the electrons to complex III. (4) Then, cytochrome c picks up the electrons 
from complex III. This process also pumps protons into the intermembrane space. (5) The 
electrons are then carried to complex IV by cytochrome c, accompanied by the 
proton-pumping process. Then oxygen, the final electron acceptor, receives the electrons and 
combines them with protons to form H2O. (6) The proton-pumping process and the electron 
transport create an electrical gradient (mitochondrial membrane potential, Δψm), which 
allows the proton transfer through the F1F0ATP synthase. Finally, the ATP is synthesized by 
adding Pi to adenosine diphosphate (ADP) [174-176].  
 
Figure 23. Mitochondrial oxidative phosphorylation [166]. 
2.3.3. Mitochondrial Respiratory Activity 
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Cellular oxygen consumption generally reveals mitochondrial respiratory activity, 
which represents a fundamental mitochondrial function. Quantification of the oxygen 
consumption rate (OCR, Figure 24) is one of the best choices to detect mitochondrial 
dysfunction [177]. The basal oxygen consumption rate reflects the coupled mitochondrial 
respiration (ATP formation), the uncoupled consumption of oxygen (formation of heat or of 
ROS) and oxygen consumption at non-mitochondrial sites. It is possible to distinguish 
between coupled and uncoupled respiration by inhibiting ATP synthase (oligomycin) and to 
determine non-mitochondrial oxygen consumption by using the complex I inhibitor rotenone. 
The maximal oxygen consumption rate caused by the addition of mitochondrial uncoupling 
agents (carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP)) provides an 
indication on the energy storage capacity [178, 179]. 
 
Figure 24.	Oxygen consumption rate (OCR) is measured by Seahorse assay [180]. 
2.3.4. Mitochondrial Membrane Potential 
The electrical potential difference between the mitochondrial matrix and the cytosol is 
one of the postulates of the chemiosmotic theory of oxidative phosphorylation [181, 182]. 
Nowadays, it is well known as mitochondrial membrane potential (Δψm) [183]. 
Mitochondria use proton electrochemical gradient potential or electrochemical proton 
dynamics (Δp) to generate ATP [184, 185]. The Δp is a combination of mitochondrial 
membrane potential (Δψm) and mitochondrial pH gradient (ΔpHm) [184, 185]. Δp provides 
is the driving force for bioenergy (ATP) production, while the Δψm provides the charge 
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gradient required for mitochondrial Ca2+ storage and regulates the production of ROS [186]. 
During cell stress, Δψm can be altered by the imbalance of intracellular ionic charge, 
affecting Δp and the production of ATP [185, 186]. For this reason Δψm can be considered a 
marker of cell health or injury [185]. 
 
2.4. Oxidative Stress 
In addition to ATP synthesis, mitochondria are also the major intracellular sources and target 
of ROS in most cell types [187]. Superoxide is considered as the main form of ROS, which is 
generated in mitochondria by incomplete reduction of molecular oxygen during oxidative 
phosphorylation [188, 189]. The main source of ROS appears to be the redox cycle 
ubiquinone in complex III. Another source is complex I, which also has many redox centres 
(Figure 25) [187]. Manganese superoxide dismutase (SOD2, an enzyme located ion the 
mitochondrial matrix) can convert superoxide to H2O2. H2O2 is more stable than superoxide 
and lipid-soluble and can be released by mitochondria easily. Although mitochondria-derived 
ROS plays a signalling role in cells, ROS may be harmful due to oxidative modification of 
proteins, nucleic acids, and lipid membranes [187]. An excess of ROS can lead to oxidative 
stress, a harmful process that can damage several cellular structures, such as proteins, lipids, 
lipoproteins, membranes and DNA	[190-194]. At this point, cells need specific mechanisms 
to eliminate ROS in order to restore normal physiological conditions	[194]. The superoxide 
dismutase (SOD) family can be used to catalyze the initial reaction of ROS	to water through 
glutathione peroxidase and catalase (Figure 25)	[195]. Many studies in vivo have supported 
the involvement of oxidative stress in drug-induced toxicity [27, 196].  
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Figure 25.	The production and elimination of mitochondrial ROS. 
2.5. Mechanisms of Cell Death 
There are mainly three forms of cell death: necrosis, apoptosis, and autophagy-
associated cell death [197]	 A comparison of necrosis, apoptosis, and autophagy is 
presented in Table 3 [197, 198]. 
 
Table 3. Comparison of necrosis, apoptosis and autophagy. 
  
2.5.1. Necrosis 
Necrosis (Figure 26) is a classical mechanism of cell death, which can occurred by 
factors external to the cell or tissue [199]. The morphological characteristics of necrosis are 
cell swelling and lysis, chromatin flocculation, disintegration of organelles, extensive DNA 
hydrolysis, vacuolation of the endoplasmic reticulum, and organelle breakdown [199, 200]. 
Characteristic Necrosis Apoptosis Autophagy 
Causative factors
Severe oxidative stress
Ischemia
Hyperthermia
Hypoxia
High concentrations of toxic 
substances
Chemotherapy(?)
Moderate oxidative stress
Deficiency of growth factors
HIV
Chemotherapy
Irradiation
Induction of death receptors
Nutrient deprivation
Growth factor depletion 
Hypoxia
Endoplasmic reticulum stress
Pathogen infection
Morphological Characteristics
Chromatin flocculation
Membrane damage
Disintegration of organelles
Cell swelling
Cell lysis
Secondary necrosis can occur in the 
late stage of apoptosis
Condensation of chromatin
Intact cell membrane with blebs but 
the membrane may be damaged in the 
late stage in vitro
Shrinkage of cell
Apoptotic body formation
Double- or multiple-membrane 
enclosed vesicles in the cytoplasm 
Engulf portions of cytoplasm and/or 
organelles such as mitochondria and
endoplasmic reticulum. 
Vesicles fuse with lysosomes
Biochemical/Immunological
Characteristics
Impaired ion homeostasis ATP is not 
required
DNA gives a smear pattern in agarose
gel electrophoresis
Total cell death markers (LDH, M65) 
are released
Lysosomal enzymes are released and
inflammation occurs
ATP is required
Internucleosomal DNA 
fragmentation(ladder pattern in 
agarose gel electrophoresis)
Caspase-cleaved cytokeratin 18 (M30 
antigen) is released
Inflammation does not occur
Caspase activation very late if at all
Primary proteases are cathepsins or 
proteasomal proteins
DNA fragmentation very late if at all
Exteriorization of phosphatidylserine
No inflammation
Methods to Assess
M65 ELISA assay (detects both 
necrosis+apoptosis) 
Lactate dehydrogenase (LDH) 
determination
Cytochrome c release
M30 ELISA assay
Caspase-3 activation
Sub G1 peak inflow cytometry
Electron microscopy
Immuno-gold labeling on ultrathin 
cryosections
LC3 determination
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Figure 26.	The cellular changes in necrosis [201]. 
2.5.2. Apoptosis 
Apoptosis (Figure 27) is a programmed form of cell death first identified and named 
by John Kerr and Andrew Wyllie in 1972 [202]. It is far distinct from necrosis and can occur 
under physiological and pathological conditions. Morphologically, apoptotic cells decerase 
the cellular and nuclear volume, condense the chromatin, show cell shrinkage and loss of 
surface microvilli, have an intact cell membrane with blebs and internucleosomal DNA 
fragmentation [203]. ATP is required for this process. 
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Figure 27.	The cellular changes in apoptosis [201]. 
At the molecular level, apoptosis can occur by two signaling mechanisms (Figure 28): 
intrinsic pathway and extrinsic pathway. The intrinsic pathway is initiated by internal sensors 
of severe cell distress, and regulated by Bcl-2 family proteins [204]. These triggers are 
collectively called “stress signals” and include DNA damage, loss of cellular adhesion, 
growth factor withdrawal, cytoskeleton disruption, hypoxia, endoplasmic reticulum stress, 
macromolecular synthesis inhibition and many more. The extrinsic pathway is triggered by 
extracellular specific ligands through the engagement of death receptors (DR) at the cell 
surface [205]. It also means that both physiological and pathological conditions can result in 
cell apoptosis. Downstream effects of the two pathways lead to the activation of the 
executioner caspases (cysteine-aspartic acid protease) [206]. Furthermore, mitochondrial 
dysfunction also can trigger apoptosis [207]. 
Caspases are a family of endoproteases that play essential roles in regulating cell 
death and controlling inflammation [208]. The most important function of them is to 
participate in programmed cell death (apoptosis, pyroptosis and necroptosis) and 
inflammation. Caspases are divided into two categories due to their roles in apoptosis 
(caspase 3, 6, 7, 8, and 9 in mammals) and inflammation (caspase 1, 4, 5, 12 in humans and 
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caspase 1, 11, and 12 in mice). During apoptotic processes, caspases can disassembly the cell 
into apoptotic bodies. Caspases 8, 9 and 3 are considered as key pivots to initiate the 
apoptotic pathways. 
Caspase 8 is responsible for the extrinsic apoptosis pathway [209]. The extrinsic 
apoptosis pathway is triggered by the external ligand binding to the death receptors (DRs). 
When a ligand binds to a DRs, it results in the dimerization and activation of caspase 8 by the 
adapter proteins (FADD/TRADD) [208]. 
Caspase 9 plays an important role in the intrinsic apoptosis pathway (mitochondrial 
apoptosis) [210]. The process of caspase 9 activation is as follows: first, cellular stresses lead 
to the release of cytochrome c from the mitochondria and to the formation of apoptosome 
[211]. Then, the binding of cytochrome c to apoptotic protease activates factor 1 (APAF-1) 
monomer and results into conformational changes with exposure of a nucleotide-binding site 
and oligomerization of APAF-1. Next, the caspase recruitment domain (CARD) of caspase 9 
binds to APAF-1. Finally, the extra-mitochondrial cytochrome c, caspase 9, ATP and 
APAF-1 form the apoptosome which activates caspase 3 [211] [212]. 
Caspase 3 is a key death protease that amplifies signals of caspase 8 and caspase 9 
to commit disassembly of vital cellular proteins or other caspases [213, 214]. It can be 
activated by both extrinsic and intrinsic apoptosis pathways [215, 216]. Caspase 3, also 
known as the executioner caspase, can be triggered by mitochondrial cytochrome c release 
and by caspase 8 and 9 activity [208, 217]. Caspase 3 is also essential to maintain the 
development of the brain [208]. 
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Figure 28.	Caspase-dependent apoptosis	[218]. 
5.3.3. Autophagy 
Autophagy is a physiological process to maintain the balance between anabolism and 
catabolism in normal cell growth and development [219]. Autophagy plays an important role 
in the response of cells to stresses, starvation, poison, and radiation [220, 221]. Autophagy is 
a strictly regulated process (Figure 29) [222, 223], it can provide substrates for energy or new 
synthesis via turning over non-essential cytoplasmic components (including organelles) [224]. 
During autophagic processes, intracellular cytoplasm, proteins, lipids, and organelle regions 
are sequestered in a double-membrane limited vacuole (autophagosomes) [225, 226]. Mature 
autophagosomes are single-membrane phagosomes and autophagosomes may become 
autolysosomes when they are acidified and acquire proteolytic enzymes by fusion with late 
endosomes or lysosomes [227, 228]. Moreover, when cells are fused with autophagosomes, 
these endocytosed substances can also trigger the autophagy pathway [229, 230]. The 
autophagic vacuole (AV) contains all the lysosomal compartments [231].	
Autophagy acts as a surveillance system when cells are stressed or injured, and it can 
remove damaged mitochondria or other organelles which may otherwise trigger apoptosis 
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[232-234]. Moreover, autodigestion caused by acute up-regulation of autophagy is also a 
form of programmed cell death [235, 236]. It is different from apoptosis but shares some 
characteristics [236]. Autophagy-induced cell death has been defined as a 
caspase-independent form of apoptosis, some cathepsins can trigger or mediate aspects of 
apoptosis and necrosis in various pathological conditions [237, 238]. 
It is noteworthy that autophagy and apoptosis interact in various ways, since (1) 
autophagy plays an essential role in the occurrence of apoptosis, (2) but autophagy may also 
prevent apoptosis, and (3) apoptosis and autophagy may appear independently [239], 
moreover, inhibition of apoptosis may induce autophagic cell death, and vice versa [240]. 
 
	
Figure 29.	The macro-autophagy process [241].	
2.6. Hyperthermia 
Hyperthermia, also known as “overheating”, is the prominent manifestations of 
stimulant drug abuse and even the primary reason for user-death [242]. The symptoms of 
stimulant drug-induced hyperthermia resembles heat stroke, the clinical manifestation is body 
temperature beyond normal [243]. According to clinical case reports, stimulant drug-induced 
hyperthermia can result in many fatal complications such as hyponatremia, rhabdomyolysis, 
brain edema, disseminated intravascular coagulation and coma [244]. Hyperthermia is very 
common, especially when these drugs are ingested in crowded clubs with high ambient 
temperatures and excessive physical exertion [245]. A large number of hyperthermia-
associated clinical cases caused by amphetamines and synthetic cathinones have been 
reported so far [246, 247]. These drugs can increase users’ body temperature over 40°C, 
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which may lead to life-threatening conditions [246]. Base on some surveys, more than 60% 
users of 4-MMC (mephedrone) have hyperthermic subjective effects [248]. Methcathinone 
and 4-CMC have also been reported to cause hyperthermia [11, 57]. Furthermore, the 
combination of these drugs induces an impairment of thermoregulation and promotes toxicity, 
resulting in more frequent and serious cases of hyperthermia [249, 250].
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Inhibition	Properties	and	Hepatocellular	Toxicity	of	
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In this paper, we investigated the pharmacological perspective and hepatocellular 
toxicity of amphetamine, 4-FA, PCA, methcathinone, 4-FMC and 4-CMC in HepG2 
cells. 
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3. Paper 3 
 
Para-halogenation	of	Amphetamine	and	
Methcathinone	Increases	the	Mitochondrial	Toxicity	
in	Undifferentiated	and	Differentiated	SH-SY5Y	Cells	
 
In this paper, we investigated the mitochondrial toxicity of amphetamine, 4-FA, PCA, 
methcathinone, 4-FMC and 4-CMC in undifferentiated and differentiated SH-SY5Y 
cells.   
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Abstract: Halogenation of amphetamines and methcathinones has become a common method to
obtain novel psychoactive substances (NPS) also called “legal highs”. The para-halogenatedderivatives
of amphetamine and methcathinone are available over the internet and have entered the illicit drug
market but studies on their potential neurotoxic e↵ects are rare. The primary aim of this study was to
explore the neurotoxicity of amphetamine, methcathinone and their para-halogenated derivatives
4-fluoroamphetamine (4-FA), 4-chloroamphetamine (PCA), 4-fluoromethcathinone (4-FMC), and
4-chloromethcathinone (4-CMC) in undi↵erentiated and di↵erentiated SH-SY5Y cells. We found that
4-FA, PCA, and 4-CMC were cytotoxic (decrease in cellular ATP and plasma membrane damage) for
both cell types, whereby di↵erentiated cells were less sensitive. IC50 values for cellular ATP depletion
were in the range of 1.4 mM for 4-FA, 0.4 mM for PCA and 1.4 mM for 4-CMC. The rank of cytotoxicity
observed for the para-substituents was chloride > fluoride > hydrogen for both amphetamines
and cathinones. Each of 4-FA, PCA and 4-CMC decreased the mitochondrial membrane potential
in both cell types, and PCA and 4-CMC impaired the function of the electron transport chain of
mitochondria in SH-SY5Y cells. 4-FA, PCA, and 4-CMC increased the ROS level and PCA and 4-CMC
induced apoptosis by the endogenous pathway. In conclusion, para-halogenation of amphetamine and
methcathinone increases their neurotoxic properties due to the impairment of mitochondrial function
and induction of apoptosis. Although the cytotoxic concentrations were higher than those needed
for pharmacological activity, the current findings may be important regarding the uncontrolled
recreational use of these compounds.
Keywords: amphetamine; methcathinone; mitochondria; neurotoxicity; para-halogenation
1. Introduction
Amphetamine is a potent central nervous system (CNS) stimulant, which is or has been used for
the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and body weight control
under restricted medical prescription [1]. The predominant pharmacological action of amphetamine
is to promote the release from [2] and inhibition of the reuptake of catecholamines into presynaptic
nerve terminals [3], causing an increase in the catecholamine concentration in the synaptic clefts
of mainly dopaminergic and noradrenergic neurons. A series of structurally similar psychoactive
substances were derived from amphetamine after 1877 when it was first synthesized. Methcathinone,
an amphetamine derivative, is currently used widely as a recreational drug [4]. Since amphetamine and
Int. J. Mol. Sci. 2020, 21, 2841; doi:10.3390/ijms21082841 www.mdpi.com/journal/ijms
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methcathinone are illicit for recreational use in most countries, many derivatives of these compounds
were synthesized as novel psychoactive substances (NPS) and labeled “legal highs” [5]. Halogenation
has been recognized as a possible method to create “legal highs” form amphetamine and derivatives [6],
and as a method to enhance their membrane binding and permeation characteristics [7]. Many reports
have documented how halogenated amphetamine derivatives such as 4-chloroamphetamine (PCA, also
called para-chloroamphetamine; 4-CA), 4-fluoroamphetamine (4-FA), and methcathinone derivatives
such as 4-chloromethcathinone (4-CMC) and 4-fluoromethcathinone (4-FMC) have lately reached the
market (Figure S1) [8–12].
However, halogenation also has the potential to increase the toxicity of the original compounds [13].
It is well known that the brain, skeletal muscle, and the liver are the most important target organs of the
toxicity of psychoactive substances [14]. Accordingly, the use of amphetamines andmethcathinones can
lead to the impairment of cognitive function, addiction, convulsions, rhabdomyolysis and acute liver
failure [15–17]. Our previous research has shown that the para-halogenated derivatives of amphetamine
andmethcathinone caused hepatotoxicity [18] andmyotoxicity [19] mainly by impairing mitochondrial
function due to disruption of the mitochondrial respiratory chain, which is associated with an increase
in the intracellular level of reactive oxygen species (ROS).
To date, systematic toxicological investigations of the para-halogenatedderivatives of amphetamine
and methcathinone in human neuron-like cells are missing. Based on these considerations, the aim of
the current study was to investigate the in vitro mechanisms causing neurotoxicity of amphetamine,
4-FA, PCA, methcathinone, 4-FMC, and 4-CMC, using the well-established SH-SY5Y cell model in the
di↵erentiated and undi↵erentiated states [20–22].
2. Results
2.1. Cell Di↵erentiation
As the first step in our study, we validated our protocol of differentiation of SH-SY5Y cells by
immunohistofluorescence (Figure S2). Microtubule-associated protein 2 (MAP2) and neurofilament heavy
polypeptide (NF-H) are well-known markers of differentiation of SH-SY5Y cells [20]. In undifferentiated
SH-SY5Y cells, MAP2 was distributed strongly within the perinuclear area, but weakly in the neurites,
and the expression of NF-H was restricted mainly to the cell soma (Figure S2A) [20]. Moreover, the
neuritic processes were short and almost undetectable in undifferentiated cells. A different pattern
of immunoreactivity and cell morphology was observed in ATRA/BDNF-differentiated SH-SY5Y cells
(Figure S2B). MAP2 and NF-H expression was not only restricted to the cell soma but strongly present in
the neurites as well, indicating the typical differentiation of SH-SY5Y cells to neuron-like cells. Finally,
differentiated SH-SY5Y cells showed phenotypical characteristics of neurons, in particular a pyramidal
body shape with longer projections, similar to dendrites and axons [22].
2.2. Cell Membrane Integrity and ATP Content
The release of adenylate kinase (AK) was measured as a marker for cell membrane integrity,
and the intracellular ATP content was assessed to determine mitochondrial function (Figures 1
and 2, respectively). Undi↵erentiated and di↵erentiated SH-SY5Y cells were treated with increasing
concentrations of amphetamine, 4-FA, PCA, methcathinone, 4-FMC, and 4-CMC (see Figure S1 for
the chemical structures of these compounds). All of these compounds were membrane toxic and
decreased the intracellular ATP content in a concentration-dependent manner, with the exception of
methcathinone and 4-FMC, which did not show any toxicity up to 2000 µM.
Results	
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kinase (AK) compared to control (controls: DMSO 0.1% set as 0%, Triton X set as 100%). Data are 
expressed as mean ± SEM of eight independent experiments. Statistical differences were calculated 
with one-way ANOVA followed by the Dunnett’s test, (*) p ≤ 0.05 and (***) p ≤ 0.001 versus 0.1% 
DMSO control. 
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Figure 1. Plasma embrane integrity in undi↵erentiated and di↵erentiated SH-SY5Y cells.
(A)Undi↵er ntiated and (B) di↵erentia ed SH-SY5 cells were xposed to amphetamine, 4-FA and PCA
for 24 h. (C) Undi↵erentiated and (D) di↵erentiate SH-SY5Y cells were exposed to methcathinone,
4-FMC and 4-CMC for 24 h. Data are expressed s percentage of release of adenylate kinase (AK)
compared to control (controls: DMSO 0.1% et as 0%, Triton X set as 100%). Data are expressed as mean
± SEM of eight independent experiments. Statistical di↵erences were calculated with one-way ANOVA
followed by the Dunnett’s test, (*) p  0.05 and (***) p  0.001 versus 0.1% DMSO control.
The exposure of undi↵erentiated SH-SY5Y to amphetamine, 4-FA, and 4-CMC for 24 h was
significantly membrane toxic at 2000 µM, whereas PCA was toxic already at 500 µM (Figure 1A,C).
A similar pattern was observed in di↵erentiated cells for 4-FA, PCA, and 4-CMC, but not for
amphetamine (Figure 1B,D). Moreover, membrane toxicity of PCA in di↵erentiated cells started
already at 200 µM (Figure 1A,B). The intracellular ATP content started to decrease in undi↵erentiated
cells at 200 µM for PCA, at 500 µM for 4-FA and 4-CMC, and at 1000 µM for amphetamine, whereas
methcathinone and 4-FMC were not toxic up t 2000 µM (Figure 2A,C). In di↵erentiated cells, only
PCA (starting at 500 µM), 4-FA (starting at 1000 µM) and 4-CMC (starting at 1000 µM) were toxic,
whereas amphetamine, methcathinone and 4-FMC did not significantly decrease the cellular ATP pool
(Figure 2C,D). Table 1 presents the IC50 values of cellular membrane toxicity and ATP depletion for the
compounds investigated. The values show a more pronounced e↵ect regarding the diminution of the
cellular ATP content as compared to the membrane toxicity, a pattern suggesting mitochondrial toxicity.
Table . Quantification (IC50) of membrane toxicity (MT) and ATP depletion (ATP) by para-halogenated
amphetamine (Amph) andmethcathinone (MC) derivatives in undi↵erentiated (und), and di↵erentiated
(di↵) SH-SY5Y cells.
Drug Amph 4-FA PCA MC 4-FMC 4-CMC
Cell und di↵ und di↵ und di↵ und di↵ und di↵ und di↵
MT (IC50)
[mM] >2 >2 >2 >2 1.17 0.77 >2 >2 >2 >2 >2 >2
ATP (IC50)
[mM] >2 >2 1.44 1.41 0.42 0.39 >2 >2 >2 >2 1.43 1.33
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Figure 2. Intracellular ATP content in undi↵erentiated and di↵erentiated SH-SY5Y cells. (A)
Undi↵erentiated and (B) di↵erentiated SH-SY5Y cells were exposed to amphetamine, 4-FA and
PCA for 24 h. (C) Undi↵erentiated and (D) di↵erentiated SH-SY5Y cells were exposed tomethcathinone,
4-FMC and 4-CMC for 24 h. Data are expressed as percentage of ATP content compared to control
(controls: DMSO 0.1% set as 100%, Triton X set as 0%. Data are expressed as mean ± SEM of eight
independent experiments. Statistical di↵erences were calculated with one-way ANOVA followed by
the Dunnett’s test, (*) p  0.05, (**) p  0.01 and (***) p  0.001 versus 0.1% DMSO control.
2.3. Mitochondrial Membrane Potential
In order to confirm mitochondrial toxicity, we determined the mitochondrial membrane potential
(D m) using JC-1 staining. Mitochondrial toxicants have been shown to decrease the mitochondrial
membrane potential in SH-SY5Y cells [23]. Each of 4-FA, PCA and 4-CMC decreased the D m
in a concentration-dependent manner in both cell models (Figure 3A–D), whereas amphetamine,
methcathinone and 4-FMC were not toxic up to 2000 µM. Similar to cytotoxicity, PCA was the most
toxic compound investigated, starting to decrease D m at 500 µM in undi↵erentiated and at 200 µM in
di↵erentiated SH-SY5Y cells exposed for 24 h (Figure 3A,B). In comparison to the amphetamines, the
methcathinones were less toxic.
These data confirmed our results obtained for the depletion of the cellular ATP content and
indicated that 4-FA, PCA and 4-CMC are mitochondrial toxicants.
2.4. Cellular Oxygen Consumption
In order to understand the mechanism of mitochondrial toxicity, we determined the cellular
oxygen consumption by SH-SY5Y cells having been exposed for 24 h to the test compounds using
a Seahorse XF96 analyzer. After having obtained the basal respiration, oligomycin was injected to
inhibit complex V allowing the determination of the leak respiration as a measure of the uncoupling
of oxidative phosphorylation. This was followed by the addition of FCCP to obtain the maximal
respiration and the complex I inhibitor rotenone to obtain the non-mitochondrial respiration. Basal
respiration, leak respiration and maximal respiration are shown in Figure 4. As can be seen in all
Figures (Figure 4A–L), FCCP did not stimulate basal respiration in di↵erentiated and even inhibited
basal respiration in undi↵erentiated cells. None of the drugs stimulated the leak respiration, suggesting
Results	
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that there was no uncoupling of oxidative phosphorylation. PCA showed a concentration-dependent
e↵ect on basal respiration and respiration in the presence of FCCP in di↵erentiated cells, reaching
statistical significance at 100 µM (Figure 4F). In undi↵erentiated cells, the e↵ect of PCA was not clearly
concentration-dependent but reached statistical significance already at 50 µM (Figure 4E). Similarly,
4-CMC was toxic for undi↵erentiated and di↵erentiated SH-SY5Y cells, reaching statistical significance
for basal and stimulated respiration at 500 µM in undi↵erentiated (Figure 4K) and at 200 µM in
di↵erentiated SH-SY5Y cells (Figure 4L). A trend to decrease basal and stimulated respiration in both
cell types with 4-FMC was shown, but without reaching significance up to 1000 µM (Figure 4I,J).
In comparison, amphetamine, 4-FA, and methcathinone did not a↵ect the oxidative metabolism of
SH-SY5Y cells.Int. J. Mol. S i. 2020, 21, x FOR PEER REVIEW 5 of 18 
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of oxidative phosphorylation. This was followed by the addition of FCCP to obtain the maximal 
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respiration, leak respiration and maximal respiration are shown in Figure 4. As can be seen in all 
Figures (Figure 4A–L), FCCP did not stimulate basal respiration in differentiated and even inhibited 
basal respiration in undifferentiated cells. None of the drugs stimulated the leak respiration, 
suggesting that there was no uncoupling of oxidative phosphorylation. PCA showed a concentration-
dependent effect on basal respiration and respiration in the presence of FCCP in differentiated cells, 
reaching statistical significance at 100 μM (Figure 4F). In undifferentiated cells, the effect of PCA was 
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ex resse as mean ± SEM of five independent experiments. Statistical di↵erences were calculated with
one-way ANOVA followed by the Dunnett’s test, (*) p  0.05, (**) p  0.01 and (***) p  0.001 versus
0.1% DMSO control.
These data confirmed mitochondrial toxicity of PCA and 4-CMC, but not of 4-FA. They show that
halogenation is critical for the toxicity of these compounds and that the addition of chlorine in the
p-position is more toxic than fluoride.
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Figure 4. Oxygen consumption by undi↵erentiated and di↵erentiated SH-SY5Y cells expressed as
basal, leak, and maximal respiration. Undi↵erentiated and i↵ cel s were xposed
to (A,B) mphetamine, (C,D) 4-FA, (E,F) PCA, (G,H) methcathinone, (I,J) 4-FMC, and (K,L) 4-CMC for
24 h. Data are expressed as mean ± SEM of seven independent experiments. Statistical di↵erences
were calculated with one-way ANOVA followed by the Dun ett’s t st, (*) p  0.05, (**) p  0.01 v rsu
0.1% DMSO control.
2.5. Mitochondrial Superoxide Production
Toxicants inhibiting the function of the mitochondrial electron transport chain can increase the
production of mitochondrial ROS [19,24]. Therefore, we determined mitochondrial production of the
superoxide anion in undi↵erentiated and di↵erentiated SH-SY5Y cells exposed to test drugs for 24 h
(Figure 5).
In both undi↵erentiated and di↵erentiated SH-SY5Y cells exposed to 4-FA, mitochondrial
superoxide production started to increase at the highest concentration of 2000 µM (Figure 5A,B).
Concerning PCA, only undi↵erentiated SH-SY5Y cells showed a significant increase of the cellular
ROS content, which started at 500 µM (Figure 5A), whereas the di↵erentiated cells were more resistant
with a trend for an increase at 2000 µM (Figure 5B). The exposure to 4-CMC increased the superoxide
anion content in both cell models starting at 2000 µM (Figure 5C,D). The other drugs investigated did
not increase the mitochondrial superoxide production in the investigated concentration range (up to
2000 µM).
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i r 5. Mitochondrial superoxide accumulation was measured in undi↵ere tiate and di↵erentiate
SH-SY5Y cells after exposure to drugs for 24 h. (A) Undi↵erentiated and (B) i↵erentiate SH-SY5Y
cells were exposed to amphetamine, 4-FA and PCA for 24 h. (C) Undi↵erentiated and (D) di↵erentiated
SH-SY5Y cells were exposed to methcathinone, 4-FMC and 4-CMC for 24 h. Data are expressed as
mean ± SEM of five independent experiments. Statistical di↵erences were calculated with one-way
ANOVA followed by the Dunnett’s test, (**) p  0.01 and (***) p  0.001 versus 0.1% DMSO control.
2.6. Mechanisms of Cell Death
When themitochondrial damage becomes too large, cells undergo apoptosis or necrosis, depending
on the cellular ATP content [25]. In order to investigate the mechanism of cell death, we assessed the
externalization of phosphatidylserine by annexin V binding, and the permeability of the cell membrane
to propidium iodide (PI), as markers of apoptosis and necrosis, respectively. H2O2 (500 µM) was used
as a positive control (Figure 6) [26]. In undi↵erentiated SH-SY5Y cells exposed for 6 h, PCA increased
necrosis starting at 200 µM, reaching statistical significance at 500 µM (Figure 6A). 4-CMC induced
apoptosis starting at 1000 µM and reached statistical significance at 2000 µM. Similar to PCA, 4-FA
also increased necrosis (starting at 2000 µM), whereas the other compounds did not induce apoptosis
or necrosis up to 2000 µM. In di↵erentiated SH-SY5Y cells, PCA induced necrosis starting at 100 µM,
reaching statistical significance at 500 µM (Figure 6B). 4-CMC induced apoptosis starting at 500 µM,
reaching statistical significance at 1000 µM, and necrosis starting at 2000 µM. 4-FA induced necrosis
starting at 2000 µM, whereas the other compounds were ine↵ective. The shorter incubation time (6 h
versus 24 h) was selected to focus on the early apoptosis phase rather than on necrosis.
To confirm the activation of apoptotic pathways and to find out the mechanism of activation,
we assessed the activation of caspases 3 and 9 in the presence of 4-CMC at 6 h of incubation. We
chose 4-CMC for these experiments, since only 4-CMC, and not PCA or 4-FA, induced apoptosis of
SH-SY5Y cells at 6 h of incubation. Caspase 9 is activated in response to the intrinsic apoptotic pathway,
whereas caspase 3 is an executioner caspase [27,28]. The intrinsic pathway can be defined as the
mitochondrial pathway, since damaged mitochondria release cytochrome c, which activates caspase
9 [29]. To confirm that 4-CMC causes apoptosis and to assess by which pathway, we determined the
expression of cleaved caspase 3 and 9 by immunoblotting after drug exposure for 6 h (Figure 7A,B) [30].
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Amiodarone (50 µM) and MDMA (500 µM) were used as negative controls regarding the induction of
apoptosis. As shown in Figure 7A, 2000 µM 4-CMC increased the abundance of cleaved caspase 3
in both undi↵erentiated and di↵erentiated SH-SY5Y cells, confirming the results obtained with the
annexin V assay. Moreover, 4-CMC increased the expression of cleaved caspase 9 at 2000 µM in both
di↵erentiated and undi↵erentiated SH-SY5Y cells (Figure 7B).
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Figure 7. E↵ects on markers of apoptosis in undi↵erentiated and di↵erentiated SH-SY5Y cells exposed
to drugs for 6 h. (A) Activation of caspase 3 and (B) activation of caspase 9. Data are expressed as
mean ± SEM of eight independent experiments for each drug concentration. Statistical di↵erences were
calculated with one-way ANOVA followed by the Dunnett’s test, (*) p  0.05, and (***) p  0.001 versus
0.1% DMSO control.
3. Discussion
We found that both halogenated amphetamines were cytotoxic (membrane damage and/or ATP
depletion) for undi↵erentiated anddi↵erentiated SH-SY5Y cells, with a similar concentration-dependent
pattern. Among the halogenated methcathinones, only 4-CMC showed plasma membrane toxicity
and ATP depletion. Amphetamine was cytotoxic at the highest concentration investigated, whereas
methcathinonewas not cytotoxic up to 2mM. The rank of cytotoxicity observed for the para-substituents
was chloride > fluoride > hydrogen for both amphetamines and cathinones. Both PCA and 4-CMC
impaired the function of the mitochondrial electron transport chain and increased mitochondrial
superoxide production. In general, di↵erentiated SH-SY5Y were less sensitive to the chemicals
investigated than undi↵erentiated cells.
The amphiphilic nature of amphetamines and methcathinones enables them to cross the
blood-brain barrier and to reach the neurons, their site of pharmacological action. As known from case
reports and as shown in the current study, this has not only an impact on the pharmacological e↵ect
but also on the neurotoxicity of these compounds. Halogenation in the para-position not only increases
lipophilicity of these chemicals but also blocks para-hydroxylation, prolonging the pharmacological
and toxicological e↵ects of these compounds in vivo [31].
In the current investigations, 4-FA, PCA and 4-CMC decreased the cellular ATP content at lower
concentrations than impairing membrane integrity (Table 1 and Table S1). This is a typical feature of
toxicants that impairmitochondrial function [32,33] and is in linewith our previous investigations on the
hepatocellular toxicity of amphetamine, methcathinone and their para-halogenated forms [3,13,34,35].
A decrease in the cellular ATP content is also one of the first hints of mitochondrial perturbation,
since mitochondria are the main site of ATP production in most cells, although glycolysis may also
contribute when glucose is available [36]. The significant drop in the D m, which appeared at similar
concentrations as the decrease in the cellular ATP pool (Table S1), confirmed that mitochondria are the
target of the p-halogenated amphetamine compounds and of 4-CMC [37]. These findings are consistent
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with the observations ofChen et al., who investigated the toxicity of amphetamines in apulmonary artery
model [18,38] and of Luethi et al., who studied the mechanisms of hepatocellular toxicity associated
with new synthetic cathinones [18,38]. Investigations of the e↵ects on mitochondrial respiration
revealed that PCA and 4-CMC reduced basal and maximal respiration of both undi↵erentiated and
di↵erentiated SH-SY5Y cells, whereby PCA was slightly more toxic than 4-CMC. While amphetamine
and methcathinone were not toxic up to 2000 µM, the fluorinated derivatives decreased basal and
maximal respiration by trend in both cell types studied. The toxicity rank order of the substituents
in the p-position for disturbing mitochondrial function was therefore for both amphetamines and
methcathinones (Cl > F >H), which was also the case for cytotoxicity. The current study revealed a
decrease in oxygen consumption by SH-SY5Y cells in the presence of 4-FA, PCA and 4-CMC, indicating
impaired function of the electron transport chain. The results do not, however, allow to conclude which
enzyme complexes of the electron transport chain are a↵ected. In a previous study, we have shown
that the amphetamine-like MDMA reduced the activity of complexes I and III, and the cathinones
↵-pyrrolidinopentiophenone (↵-PVP) and naphyrone complex I and complex II, respectively, in C2C12
cells, a mouse skeletal muscle cell line [19]. Inhibition of complex I and/or complex III could explain
the results obtained in the current study.
Defective mitochondrial respiration can lead to an increase in mitochondrial ROS levels [3,39].
It is known that the neurotoxicity of amphetamines is at least partially due to an increased cellular
ROS accumulation caused by oxidative deamination of catecholamines, depletion of antioxidant
systems and/or mitochondrial dysfunction [24,40–44]. In addition, Naserzadeh et al. have shown
that 4-methylmethcathinone (4-MMC), a new and popular drug of abuse, increases mitochondrial
ROS levels and damages the outer mitochondrial membrane in mitochondria obtained from the
hippocampus, cortex, and cerebellum of rats [45]. In the current study, we observed a significant
increase in the mitochondrial ROS content in the presence of 4-FA, PCA and 4-CMC in undi↵erentiated
SH-SY5Y cells, which is in line with the studies mentioned above.
Mitochondrial ROS generation can have di↵erent consequences for cells, eventually leading to
oxidation of DNA, membrane lipids and proteins and finally cell death. Superoxide generated mainly
by complex I or III within the mitochondria can be degraded by superoxide dismutase 2 (SOD2) to
H2O2, which can leave the mitochondria and oxidize KEAP1 in the cytoplasm [46]. This process
stabilizes and activates NRF2, a nuclear transcription factor, which stimulates the transcription of genes
associated with antioxidative defense, such as SOD2 and many others [47]. An additional defense
mechanism that can be activated by ROS-induced accumulation of misfolded proteins and/or organelle
damage is autophagy [48]. We have shown in a recent study that 4-CMC stimulates autophagy in
SH-SY5Y cells [49], demonstrating the activation of antioxidative defensemechanisms. If mitochondrial
superoxide generation is too extensive, mitochondrial superoxide accumulation can lead to an opening
of the permeability transition pore (mPTP), which is associated with a drop in the mitochondrial
membrane potential and release of cytochrome c into the cytoplasm with induction of apoptosis [50,51].
This is in line with the activation of caspases 9 and 3 observed in the current study, which proves the
stimulation of the endogenous apoptotic pathway by 4-CMC.
When compared to di↵erentiated cells, the e↵ects of PCA and 4-CMC were less accentuated
than in undi↵erentiated cells and the e↵ect of 4-FA was not significant. In agreement with these
findings, Schneider et al. showed that the regulation of glycolysis and oxidative phosphorylation is
modulated during cell di↵erentiation, which can a↵ect the way cells respond to toxicants causing
oxidative stress [52]. In line with this notion, ATRA-induced cell di↵erentiation has been shown
to confer resistance to compounds inducing oxidative stress [53]. However, despite an increase in
antioxidative capacity during the di↵erentiation of SH-SY5Y cells [20,22,24], treatment with PCA and
4-CMC caused high enough cellular ROS levels to induce apoptosis.
There are reports in the literature that show how the use of methamphetamine is linked to the
development of Parkinson’s syndrome. In an epidemiological study, an increased risk to develop
Parkinson’s syndrome by a factor of 1.5–3 has been reported in amphetamine consumers [54,55].
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Parkinson’s syndrome develops due to a loss of dopaminergic neurons in the nigrostriatal system,
which may be caused by mitochondrial damage [56]. Therefore, the current study suggests that
para-halogenation of amphetamines and methcathinones may increase this risk. If confirmed, this is an
important finding, which may have an impact on the use of these compounds.
In comparison to their pharmacological activity, which is observed in the high nanomolar to
low micromolar range, depending on the compound and the pharmacological e↵ect considered [3],
cytotoxicity was detected at clearly higher concentrations in the current study. Plasma concentrations
reached for amphetamine after a pharmacological dose are in the low micromolar range [57] and
PCA started to be toxic at 50 to 100 micromolar. A possible explanation for this discrepancy between
pharmacological activity and toxicity may be that cell lines as used in the current study may be less
sensitive to toxicants than primary cells. This has for instance been shown for human hepatocyte
cell lines and primary human hepatocytes [58]. Furthermore, patients presenting with neurotoxicity
usually have ingested higher than pharmacological doses of these compounds, may have ingested
other toxic drugs and/or alcohol and may have an elevated body temperature. It has recently been
shown that the hepatocellular toxicity of the synthetic cathinone 3,4-methylenedioxypyrovalerone
is more accentuated at higher temperatures [59]. In addition, since amphetamine has a volume of
distribution in the range of 3 L/kg [57], it can be assumed that the concentrations in the brain are
higher than those in plasma. Taken together, these factors may be su cient to explain the gap between
the concentrations associated with a pharmacological activity and toxic e↵ects observed for these
compounds in the current in vitro investigations.
4. Materials and Methods
4.1. Chemicals
Amphetamine, 4-fluoroamphetamine (4-FA), methcathinone, 4-fluoromethcathinone (4-FMC),
4-chloromethcathinone (4-CMC), and 3,4-methylenedioxymethamphetamine (MDMA)were purchased
from Lipomed (Arlesheim, Switzerland). 4-Chloroamphetamine (PCA) was purchased from Cayman
Chemical (Ann Arbor, MI, USA). All drugs were racemic hydrochloride salts with a HPLC purity of
>98%. Test drugs were dissolved in DMSO and stored at -20  C, then serially diluted in DMSO to
avoid precipitation, followed by dilution in medium or assay bu↵er. The final DMSO concentration
during the experiment was 0.1%.
4.2. Cell Culture and Di↵erentiation
SH-SY5Y cells were obtained from the European Collection of Authenticated Cell Cultures
(ECACC, RRID:CVCL_0019) (Sigma-Aldrich, Buchs, Switzerland). Undi↵erentiated SH-SY5Y cells
were cultured in high glucose Dulbecco’sModified Eagle’sMedium (DMEM) (Thermo Fischer Scientific,
Basel, Switzerland) supplemented with 15% heat-inactivated fetal bovine serum (FBS) (Thermo Fischer
Scientific, Basel, Switzerland), 2 mM L-glutamine (Thermo Fischer Scientific, Basel, Switzerland),
and 1 mM sodium pyruvate (Thermo Fischer Scientific, Basel, Switzerland) at 37  C in a humidified
5% CO2 atmosphere. Confluent cells (70–80%) were passaged using Gibco™ Trypsin-EDTA (0.05%)
reagent (Invitrogen, Basel, Switzerland). Neuron-like di↵erentiation of SH-SY5Y cells were induced as
described previously [20]. Briefly, SH-SY5Y cells were seeded into collagen-coated plates (Thermo
Fischer Scientific, Basel, Switzerland) at 10,000 cells/cm2. Following overnight growth, the mediumwas
replaced by culture medium supplemented with 10 µM all-trans-retinoic acid (ATRA) (Sigma-Aldrich,
Buchs, Switzerland) and the plates were incubated for five days. Finally, medium was replaced by
DMEM supplementedwith 50 ng/mL brain-derived neurotrophic factor (BDNF) (Sigma-Aldrich, Buchs,
Switzerland) and incubated for 7 days [20]. To avoid phenotypic alterations, di↵erentiated SH-SY5Y
cells were used between the 14th and 16th passage [22,60].
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4.3. Cell Di↵erentiation Determined by Microscopy
To validate the di↵erentiation protocol, we performed immunofluorescence experiments in order
to check cell morphology and the expression of di↵erentiation markers. Undi↵erentiated SH-SY5Y
cells were seeded into ibiTreat µ-Slide (Vitaris, Baar, Switzerland) one day before the assessment.
Di↵erentiated SH-SY5Y cells were grown into collagen-coated µ-Slide (Vitaris, Baar, Switzerland). For
the staining procedure, cells were fixed with 100 µL of fixation bu↵er (3.7% paraformaldehyde in PBS)
for 20 min at room temperature (RT). Then, cell permeabilization was achieved by adding 0.1% Triton®
X-100 in PBS solution for 10 min. Finally, the cells were blocked for 20 min in blocking solution (10%
goat serum, 0.1% Triton® X-100 in PBS). Afterwards, the primary antibody cocktail (anti-MAP2 clone
Poly18406, RRID:AB_256545, diluted 1:500, anti-neurofilament H clone SMI31, RRID:AB_2566782,
diluted 1:200 in blocking solution) (BioLegend, San Diego, CA, USA) was added at RT for 1 h. Then,
the cells were washed with PBS and the secondary antibody cocktail (FITC anti-rabbit clone Poly4064,
RRID:AB_893531, diluted 1:250, Alexa Fluor® 647 Goat anti-mouse IgG polyclonal, RRID:AB_2563045,
diluted 1:100, and 1.8 µMHoechst 33258 in blocking solution) (BioLegend, San Diego, CA, USA) was
added to each well and the slide was incubated at RT for 1 h with light protection [20]. Samples were
maintained in PBS and investigated using an Olympus IX83 microscope (Olympus, Shinjuku, Japan).
4.4. Cell Membrane Integrity
Membrane toxicity was assessed by measuring adenylate kinase (AK) release using the ToxiLight
Bioassay kit (Lonza, Basel, Switzerland) according to the manufacturer’s protocol [19]. Briefly,
undi↵erentiated SH-SY5Y (50,000 cells/well) and di↵erentiated SH-SY5Y (25,000 cells/well) cells were
exposed to di↵erent concentrations of amphetamine, 4-FA, PCA, methcathinone, 4-FMC, and 4-CMC
(100 µM, 200 µM, 500 µM, 1000 µM, and 2000 µM). Triton® X-100 (0.1%) was used as a positive
control to induce cell lysis. After 24 h of exposure, 20 µL of cell supernatant was transferred into a
luminescence compatible 96-well plate and 50 µL of AK detection reagent was added to each well. The
plate was incubated for 5 min at RT. The luminescence was measured on an M200 Pro Infinity plate
reader (Tecan, Männedorf, Switzerland). The percentage of intact cells (no cell membrane integrity
loss) was calculated in relation to DMSO-treated and Triton® X-100 treated cells, representing 100%
and 0% of intact cells, respectively.
4.5. ATP Content
The intracellular ATP content was measured using the CellTiter-Glo® kit (Promega, Dübendorf,
Switzerland) according to the manufacturer’s protocol [19]. Undi↵erentiated and di↵erentiated
neuronal SH-SY5Y cells were prepared as described above. Briefly, 80 µL assay bu↵er was added to
each 96-well containing 80 µL culture medium. After 15 min of incubation at RT, the ATP content was
determined by luminescence measurement using an M200 Pro Infinity plate reader (Tecan, Männedorf,
Switzerland). All data were normalized to control incubations containing DMSO 0.1%.
4.6. Mitochondrial Membrane Potential
The mitochondrial membrane potential (D m) was determined using the cationic dye 5,5,6,6-
tetrachloro-1,1,3,3-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) kit (Abcam, Cambridge, UK)
according to the manufacturer’s protocol [23]. Undi↵erentiated and di↵erentiated SH-SY5Y cells were
seeded as described above (cell membrane integrity assay) in black costar 96-well plates and exposed
to test drugs for 24 h. Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 100 µM) was
used as a positive control. FCCP is an uncoupler of mitochondrial oxidative phosphorylation and
therefore decreases D m [23]. FCCP was added to the cells for 4 h. The medium was removed and the
cells were washed with 100 µL/well of 1X dilution bu↵er from the JC-1 kit. The working JC-1 solution
(20 µM JC-1 in 1X Dilution Bu↵er) was freshly prepared and 100 µL was added into each well. The
plate was incubated for 10 min at 37  C with light protection. Then, the wells were washed twice with
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1X dilution bu↵er solution. The fluorescence was measured by an M200 Infinite Pro plate reader (Tecan,
Männedorf, Switzerland) at an excitation wavelength of 475 nm for both aggregate and monomer
forms. The emission wavelength was set at 530 nm and at 590 nm for monomer and aggregate
forms, respectively. The ratio of the fluorescence intensities between aggregates and monomers was
considered as D m. All data were normalized to control incubations containing DMSO 0.1%.
4.7. Oxygen Consumption
To measure the changes in mitochondrial respiration after test drug exposure, the mitochondrial
oxygen consumption rate (OCR) was measured with a Seahorse XF96 analyzer (Seahorse Biosciences,
North Billerica, MA, USA). Undi↵erentiated and di↵erentiated SH-SY5Y cells were cultured in XF96
Cell Culture Microplates (Seahorse Biosciences, North Billerica, MA, USA), which were pre-coated with
the cell adhesive Corning™ Cell-Tak (22.4 µg/mL, Corning, New York, NY, USA). The attached cells
were treated with culture medium containing the test drugs (PCA at a concentration of 50–200 µM and
the remaining drugs at concentrations of 200–100 µM) for 24 h. Upon treatment, the culture medium
was replaced with 175 µL per well of unbu↵ered medium (4 mM L-glutamate, 1 mM pyruvate, 1 g/L
glucose, and 63.3 mM sodium chloride, pH 7.4). Thereafter, the cells were equilibrated for 40 min in
a CO2-free incubator at 37  C, and the plate was transferred into the XF96 analyzer. Basal oxygen
consumption rates were measured prior to the automated injection of an inhibitor of F0F1ATPase
(oligomycin 1 µM). In order to assess the maximal respiratory capacity, 1 µM FCCP was applied, which
uncouples the activity of the electron transport chain from ATP synthesis. Finally, followed by the
addition of an electron transport chain complex I inhibitor (rotenone 1 µM), the non-mitochondrial
respiration rate was obtained [61]. OCR was automatically recorded by the Wave software (Seahorse
Biosciences, North Billerica, MA, USA), and data were normalized to protein content. The protein
content was determined using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Basel,
Switzerland). OCR was expressed as pmol O2 per minute per mg of protein.
4.8. Mitochondrial Superoxide Production
Mitochondrial superoxide production was determined using the MitoSOX™ Red fluorophore
probe (Thermo Fisher Scientific, Basel, Switzerland). MitoSOX is a living-cell permeant fluorogenic
dye commonly used for the detection of superoxide within mitochondria. In brief, undi↵erentiated
and di↵erentiated SH-SY5Y cells were cultured and treated in black clear-bottom 96-well plates [3].
Amiodarone (50 µM) was used as a positive control [62]. The cells were treated with the test drugs at
concentrations of 100–2000 µM for 24 h at 37  C in a CO2 incubator and then washed twice with PBS.
Subsequently, the medium was replaced by 100 µL PBS containing the MitoSOX reagent (2.5 µM) and
incubated for 10 min at 37  Cwith light protection. The fluorescence was measured at 510/580 nm using
an M200 Infinite Pro plate reader (Tecan, Männedorf, Switzerland). The results were normalized to the
protein content using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Basel, Switzerland).
4.9. Annexin V/Propidium Iodide Staining
Apoptosis (early and late apoptosis/necrosis) was determined using the Alexa Fluor® 488 annexin
V/propidium iodide (PI) staining kit, according to the manufacturer’s protocol (Vybrant TM Apoptosis
AssayKit #2) (GibcoLife Technologies, Paisley, UK) [63] andwas followedbyflowcytometric acquisition
using a Cytoflex cytometer (Beckman Coulter, Indianapolis, IN, USA). Briefly, undi↵erentiated and
di↵erentiated SH-SY5Y cells were seeded into a 24-well plates and exposed to amphetamine, 4-FA,
methcathinone, 4-FMC, or 4-CMC (1000µMand 2000µM), or PCA (100µM, 200µM, and 500µM) for 6 h
at 37  C. This shorter incubation time (6 h versus 24 h) was selected to focus on the early apoptosis phase
rather than on necrosis. Following incubation, the cells were detached and transferred into a V-well
plate. The cells were pelleted and washed twice with PBS, then 100 µL of 1X annexin-binding bu↵er
containing 5 µL of Alexa Fluor® 488 annexin V, 1 µL of PI (100 µg/mL), and 0.5 µL of anti-CD29-APC
(clone TS2/16) (BioLegend, San Diego, CA, USA) was added to each well. CD29 is a member of the
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integrin family which is expressed on the plasma membrane of undi↵erentiated and di↵erentiated
SH-SY5Y cells. Thereafter, the plate was incubated at 4  C for 15 min with light protection. For the
flow cytometry gating strategy, singlets were first identified by a forward scatter area (FSC-A) and
forward scatter height (FSC-H) gate, and then by an FSC-A and a side scatter area (SSC-A) gate. Intact
SH-SY5Y cells were distinguished from cell debris through staining with anti-CD29-APC in a FL-5 and
an SCC-A gate. Samples were analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
4.10. Western Blotting
Undi↵erentiated and di↵erentiated SH-SY5Y cells were grown into a 6-well plate and treated
with 4-CMC (500 µM, 1000 µM, and 2000 µM) for 6 h. Amiodarone 50 µM and MDMA 1000 µM
were used as negative controls [62,64]. After treatment, cells were washed twice with cold PBS bu↵er
(pH 7.4) and incubated with 70 µL of cell lysis bu↵er (radioimmunoprecipitation assay (RIPA) bu↵er
supplemented with complete protease inhibitor (Roche Diagnostics, Mannheim, Germany)) for 15 min
on ice. Then, the cell lysates were collected into Eppendorf tubes and centrifuged at 1600 g for 20 min.
The supernatants were collected and the protein concentration was quantified using the Pierce BCA
Pierce Protein Assay kit (Thermo Fisher Scientific, Basel, Switzerland). The protein extracts (18 µg
per lane) were loaded, separated by SDS/PAGE using 4–12% NuPAGE Bis-Tris gels (Invitrogen, Basel,
Switzerland), and then transferred to nitrocellulose membranes by the Trans-Blot Turbo Blotting System
(Bio-Rad, Cressier, Switzerland). After protein transfer, membranes were first incubated with blocking
bu↵er (5% non-fat drymilk in PBS containing 0.1% Tween-20 (Sigma-Aldrich, Buchs, Switzerland)) for 1
h at RT, and then incubated overnight at 4  Cwith the following primary antibodies diluted in blocking
solution: anti-cleaved caspase 3 (diluted 1:500, ab32042, RRID:AB_725947, Abcam, Cambridge, UK),
anti-caspase 3 (diluted 1:500, 8G10, RRID:AB_2069872, Cell Signaling Technology, Danvers, USA),
anti-caspase 9 (diluted 1:2000, ab52298, RRID:AB_868689, Abcam, Cambridge, UK) for full and cleaved
forms, and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (sc-365062, RRID:AB_10847862,
Santa Cruz Biotechnology, Dallas, TX, USA). The amount of GAPDH was used to correct for di↵erent
loading. Thereafter, the nitrocellulose membranes were washed three times with PBS and incubated
with secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) diluted at 1:2000 in blocking
solution for 1 h at RT. Membranes were then washed, and protein bands were developed using the
ClarityTMWestern ECL Substrate (Bio-Rad Laboratories, San Diego, CA, USA). Protein expression
was quantified using the Fusion Pulse TS device (Vilber Lourmat, Oberschwaben, Germany).
4.11. Statistics
GraphPad Prism 8.3.0 (GraphPad Software, La Jolla, CA, USA) was used for all statistical analyses.
The data are presented as the mean ± standard error mean (SEM) of at least three independent
experiments. Statistical di↵erences between the DMSO 0.1% control group and test drugs were
calculated with one-way ANOVA followed by the Dunnett’s test. A p-value < 0.05 was considered to
indicate a statistically significant di↵erence.
5. Conclusions
In conclusion, para-halogenation of amphetamine and methcathinone increases mitochondrial
toxicity associated with these drugs. The para-chlorinated and fluorinated forms were toxic on
undi↵erentiated and di↵erentiated SH-SY5Y cells in a concentration-dependent fashion, whereby the
amphetamine derivatives showed higher toxicity than the methcathinone counterparts. Moreover,
di↵erentiated SH-SY5Y cells were less susceptible to the toxic e↵ects of the compounds investigated,
possibly due to stronger antioxidative capacity. Although the cytotoxic concentrations were higher
than those needed for pharmacological activity, mitochondrial dysfunction may represent a major
mechanism for neural toxicity associated with these compounds.
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In this paper, we investigated the role of hyperthermia on methcathinone, 4-CMC, and 
4-MMC induced neurotoxicity in undifferentiated SH-SY5Y cells. 
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Abstract: Hyperthermia is one of the severe acute adverse e↵ects that can be caused by the ingestion
of recreational drugs, such as methcathinones. The e↵ect of hyperthermia on neurotoxicity is
currently not known. The primary aim of our study was therefore to investigate the e↵ects of
hyperthermia (40.5  C) on the neurotoxicity of methcathinone (MC), 4-chloromethcathinone (4-CMC),
and 4-methylmethcathinone (4-MMC) in SH-SY5Y cells. We found that 4-CMC and 4-MMC were
cytotoxic (decrease in cellular ATP and plasma membrane damage) under both hyper- (40.5  C)
and normothermic conditions (37  C), whereby cells were more sensitive to the toxicants at 40.5  C.
4-CMC and 4-MMC impaired the function of the mitochondrial electron transport chain and increased
mitochondrial formation of reactive oxygen species (ROS) in SH-SY5Y cells, which were accentuated
under hyperthermic conditions. Hyperthermia was associated with a rapid expression of the
70 kilodalton heat shock protein (Hsp70), which partially prevented cell death after 6 h of exposure to
the toxicants. After 24 h of exposure, autophagy was stimulated by the toxicants and by hyperthermia
but could only partially prevent cell death. In conclusion, hyperthermic conditions increased
the neurotoxic properties of methcathinones despite the stimulation of protective mechanisms.
These findings may be important for the understanding of the mechanisms and clinical consequences
of the neurotoxicity associated with these compounds.
Keywords: autophagy; hyperthermia; methcathinone; mitochondria; neurotoxicity
1. Introduction
New psychoactive substances (NPSs) are a broad group of drugs of abuse that are not controlled
by classic international drug laws [1]. The abuse of NPSs is a major problemworldwide, since NPSs can
elicit serious toxic e↵ects on users [2]. In recent years, several synthetic cathinones, designated as “legal
highs”, have emerged and their use as recreational drugs has grown rapidly [3]. Structurally, synthetic
cathinones are  -keto-amphetamine derivatives, with pharmacological and toxicological properties
similar to amphetamines [3]. Synthetic cathinones, such asmethcathinone (MC), 4-chloromethcathinone
(4-CMC), and 4-methylmethcathinone (4-MMC, mephedrone) (see Figure S1 for chemical structures),
have recently been recognized by the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) as emerging NPSs [4–6].
Despite clinical studies with and initial use of some synthetic cathinones for the treatment of
depression, appetite suppression, or smoking-cessation, none of these compounds have been approved
for one of these indications, mainly due to their adverse e↵ect profile [7]. Relevant adverse e↵ects
Cells 2020, 9, 965; doi:10.3390/cells9040965 www.mdpi.com/journal/cells
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reported for synthetic cathinones include anxiety, paranoia, depression, stroke, seizures, hyperthermia,
heart failure, liver failure, and even death [7,8].
Hyperthermia, also reported as “overheating”, is one of the prominent acute severe adverse
e↵ects of stimulant drug abuse, and one of the primary causes of death [9,10]. According to clinical
case reports, drug-induced hyperthermia can result in many potentially fatal complications, such
as hyponatremia, rhabdomyolysis, cerebral edema, disseminated intravascular coagulation, and
coma [11]. Drug-induced hyperthermia can be caused by several factors. Most psychostimulant drugs
can directly increase metabolic heat production by central and/or peripheral mechanisms as well as
decrease heat dissipation [9,10]. Several clinical cases of hyperthermia induced by synthetic cathinones
have been reported so far [12] and a large number of animal studies have been performed in mice and
rats to investigate the e↵ect of these compounds on the body temperature [13]. Polysubstance abuse
may contribute to methcathinone-induced hyperthermia. Additionally, a drug that may accidentally
or deliberately be used in combination with cathinones is 3,4-methylenedioxymethamphetamine
(MDMA), an amphetamine derivative with well-known e↵ects on thermoregulation [9,14]. In addition,
environmental e↵ects that users face in dancing clubs where these drugs are usually consumed may
contribute as well as to hyperthermia associated with methcathinones and MDMA [15,16].
While the capacity of cathinones and many other recreational drugs to increase the body and brain
temperature is well established, the e↵ects of hyperthermia on neurotoxicity associated with these
drugs is currently less well known [13]. Barbosa et al. investigated the e↵ect of ecstasy and ecstasy
metabolites on SH-SY5Y cells under normothermic (37  C) and hyperthermic (40  C) conditions [17].
They found that the metabolites were more toxic than the parent compound and that the toxicity
increased with higher temperature. The aim of the current study was to investigate in vitro the role of
hyperthermia on methcathinone-induced neurotoxicity using the well-established SH-SY5Y neuronal
cell model [18].
2. Materials and Methods
2.1. Chemicals and Cell Culture
Amphetamine, 4-fluoroamphetamine (4-FA), methcathinone (MC), 4-fluoromethcathinone
(4-FMC), 4-chloromethcathinone (4-CMC), 4-methylmethcathinone (4-MMC), and
3,4-methylenedioxymethamphetamine (MDMA) were purchased from Lipomed (Arlesheim,
Switzerland). 4-Chloroamphetamine (PCA) was purchased from Cayman Chemical (Ann Arbor, MI,
USA). All drugs were racemic hydrochloride salts with an HPLC purity of >98%. Test drugs were
dissolved in dimethyl sulfoxide (DMSO) and stored at  20  C. The final DMSO concentration during
the experiment was 0.1%.
The SH-SY5Y human neuroblastoma cell line was purchased from European Collection of
Authenticated Cell Cultures (RRID:CVCL_0019, ECACC) (Sigma-Aldrich, Buchs, Switzerland).
SH-SY5Y cells were cultured in a 5% CO2 incubator at 37 (normothermic conditions) or 40.5  C
(hyperthermic conditions) in high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo
Fischer Scientific, Basel, Switzerland) containing 15%heat-inactivated fetal bovine serum (FBS) (Thermo
Fischer Scientific, Basel, Switzerland), 2mML-glutamine (Thermo Fischer Scientific, Basel, Switzerland),
and 1 mM sodium pyruvate (Thermo Fischer Scientific, Basel, Switzerland).
2.2. Cell Membrane Toxicity
The release of adenylate kinase (AK) into the cell medium was assessed as a marker to measure
plasma membrane integrity. We used the ToxiLight Bioassay Kit (Lonza, Basel, Switzerland) according
to the manufacturer’s protocol. In brief, SH-SY5Y cells (50,000 cells per well) were seeded into a 96-well
Costar polystyrene plate and left to grow overnight. Afterwards, the medium was removed, and the
cells were exposed to di↵erent concentrations of PCA (from 100 to 1000 µM), amphetamine, 4-FA, MC,
4-FMC, 4-CMC, and 4-MMC (from 200 to 2000 µM). Triton X-100 (0.1%) was used as a positive control to
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induce cell lysis. MDMA (500 µM and 1000 µM) was used as a control drug, which is known to induce
hyperthermia in vivo [9]. The plate was incubated at 37 and 40.5  C in 5% CO2 and saturated humidity
for 6 and 24 h. Then, 20 µL of cell supernatant was transferred into a luminescence-compatible 96-well
plate followed by the addition of 50 µL of AK detection reagent. The plate was incubated at room
temperature (RT) for 5 min, and the luminescence was measured with a M200 Pro Infinity plate reader
(Tecan, Männedorf, Switzerland). All data were normalized to DMSO 0.1%-treated cells (control).
2.3. Intracellular ATP Content
Changes in the intracellularATP contentweremeasured using theCellTiter-Glo® kit fromPromega
(Dübendorf, Switzerland) according to the manufacturer’s protocol. SH-SY5Y cells were treated as
described above. After 6 and 24 h of treatment, 80 µL of assay bu↵er was added to each well containing
SH-SY5Y cells in 80 µL of culture medium. The plate was shaken for 2 min at 350 rpm, followed by
15 min of incubation at RT. The ATP content was determined by luminescence measurement using a
M200 Pro Infinity plate reader (Tecan, Männedorf, Switzerland). All data were normalized to DMSO
0.1%-treated cells (control).
2.4. Mitochondrial Membrane Potential
The mitochondrial membrane potential (D m) was measured using the JC-10 Mitochondrial
Membrane Potential Assay Kit (Abcam, Cambridge, UK) according to the manufacturer’s protocol.
In healthy cells, JC-10 concentrates in the mitochondrial matrix where it forms red fluorescent
aggregates, whereas, in apoptotic and necrotic cells where the D m decreases, JC-10 di↵uses out of
mitochondria, changes to a monomeric form, and stains cells with green fluorescence [19]. SH-SY5Y
cells were seeded into black Costar 96-well plates at 50,000 cells per well. Upon incubation with
di↵erent concentrations of the synthetic methcathinones (200–2000 µM) at 37 or 40.5  C for 24 h,
the supernatant was removed and the cells were rinsed with PBS. Then, 50 µL of JC-10 dye-loading
solution was added to each well and the plate was incubated for 15 min at 37  C and 5% CO2 with
light protection. Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 100 µM) was used as
a positive control. FCCP is an uncoupler of mitochondrial oxidative phosphorylation and therefore
decreases D m [20]. SH-SY5 cells were exposed to FCCP for 4 h.
The fluorescence was measured using a Tecan M200 Infinite Pro plate reader (Tecan, Männedorf,
Switzerland) at 490/525 nm for the aggregates, and at 540/590 nm for monomeric forms. The ratio of
the fluorescence intensities between aggregates and monomers was considered as an indicator of D m.
Data were normalized to control incubations containing DMSO 0.1%.
2.5. Mitochondrial Oxygen Consumption
In order to assess the changes in mitochondrial respiration due to hyperthermia in the presence
of test drugs, the mitochondrial oxygen consumption rate (OCR) was measured with a Seahorse
XF96 analyzer (Seahorse Biosciences, North Billerica, MA, USA). SH-SY5Y cells were seeded at a
density of 50,000 cells per well into XF96 Cell CultureMicroplates (Seahorse Biosciences, North Billerica,
MA, USA) coated with the cell adhesive Corning™ Cell-Tak (22.4 µg/mL) (Corning, New York, USA).
SH-SY5Y cells were left to grow overnight and then treated with di↵erent concentrations of test drugs
(200, 500, and 1000 µM) for 24 h at 37 and 40.5  C. Before the measurement, SH-SY5Y cells were rinsed
twice with unbu↵ered DMEM medium (4 mM L-glutamate, 1000 µM pyruvate, 1 g/L glucose, and
63.3 mM sodium chloride, pH 7.4) and equilibrated in a CO2-free incubator for 30 min. First, basal
oxygen consumption was measured, then the leak respiratory rate after automated injection of an
ATP synthase inhibitor (oligomycin 1 µM). Maximal OCR was determined by adding FCCP (1 µM).
Finally, the non-mitochondrial respiration rate was obtained by the addition of an electron transport
chain complex I inhibitor (rotenone 1 µM). OCR was automatically recorded by the Wave software
(Seahorse Biosciences, North Billerica, MA, USA), and data were normalized to the protein content
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determined using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Basel, Switzerland).
OCR was expressed as pmol O2 per minute per mg of protein.
2.6. Mitochondrial Superoxide Production
Mitochondrial superoxide production was assessed using the MitoSOX™ Red fluorophore probe
(Thermo Fisher Scientific, Basel, Switzerland). SH-SY5Y cells were seeded into a black 96-well plate at
a density of 50,000 cells per well, treated with the synthetic methcathinones at di↵erent concentrations
(from 200 to 2000 µM), and incubated for 24 h at 37 or 40.5  C. Amiodarone (50 µM) was used as
a positive control [21]. MDMA (500 and 1000 µM) was used as a control drug known to induce
hyperthermia in vivo [9]. Upon treatment, the medium was removed, and the cells were rinsed with
PBS. Next, 100 µL of PBS containing MitoSOX reagent (2.5 µM) was added to each well and the plate
was incubated for 10 min at 37  C with light protection. The fluorescence was measured using a
Tecan M200 Infinite Pro plate reader (Tecan, Männedorf, Switzerland) at 510/580 nm. The results were
normalized to the protein content quantified by the Pierce BCA Protein Assay kit (Thermo Fisher
Scientific, Basel, Switzerland) and to DMSO 0.1%-treated control cells.
2.7. Apoptosis
Apoptosis (early and late apoptosis/necrosis) was determined using the Alexa Fluor® 488 annexin
V/propidium iodide (PI) staining kit, according to the manufacturer’s protocol (Vybrant TM Apoptosis
Assay Kit #2) (Gibco Life Technologies, Paisley, UK) and followed by flow cytometric acquisition using
a Cytoflex cytometer (Beckman Coulter, Indianapolis, IN, USA). Briefly, SH-SY5Y cells were seeded into
a 48-well plate at a density of 200,000 cells per well and left to grow overnight. The cells were treated
with MC, 4-CMC, 4-MMC at 1000 and 2000 µM, and MDMA at 500 and 1000 µM, for 6 and for 24 h at
37 and 40.5  C. H2O2 (500 µM) was used as a positive control for apoptosis [22]. The 6-h incubation
time was selected to focus on the early apoptosis phase rather than on the necrosis. On the day of
measurement, the cells were transferred into a V-well plate, pelleted, and washed twice with PBS.
Then, 100 µL of 1⇥ Annexin-Binding Bu↵er containing 5 µL of Alexa Fluor® 488 annexin V, 1 µL
of PI (100 µg/mL), and 0.5 µL of anti-CD29-APC (RRID:AB_314323, clone TS2/16) (BioLegend, San
Diego, CA, USA) was added to each well. CD29 is a member of the integrin family expressed on the
membrane of SH-SY5Y cells [23]. Thereafter, the plate was incubated at 4  C for 15 min with light
protection. For the flow cytometry gating strategy, singlets were first identified by a forward scatter area
(FSC-A) and forward scatter height (FSC-H) gate, and then by an FSC-A and side scatter area (SSC-A)
gate. Intact SH-SY5Y cells were distinguished from cell debris by staining with anti-CD29-APC in a
FL5-A/SCC-A dot plot. Samples were analyzed using FlowJo software, Tree Star (RRID:SCR_008520)
(Ashland, OR, USA).
2.8. Western Blotting
SH-SY5Y cells were seeded into 6-well plates and left to grow overnight. For the assessment
of Hsp70, caspase 3, LC3 I, and LC3 II, cells were treated with methcathinones (MC, 4-CMC, and
4-MMC) at the concentrations of 1000 and 2000 µM, and with MDMA at 500 and 1000 µM at 37 or
40.5  C. Concanamycin A (100 nM) and bafilomycin A (100 nM) (Tocris Bioscience, Abingdon, UK)
were used as positive controls for the inhibition of autophagy [24]. Hsp70 and caspase 3 were
quantified after 6 h of incubation, LC3 I and LC3 II were quantified after 24 h of incubation. Upon
treatment, cells were lysed using radioimmunoprecipitation assay (RIPA) bu↵er with complete protease
inhibitor (Roche Diagnostics, Mannheim, Germany) on ice for 15 min and then centrifuged to obtain
protein samples. Following the collection of supernatants, BCA Pierce assay was used to quantify the
protein concentration of each sample. Afterwards, a total of 18 µg protein per sample was loaded
and run onto a 4–12% SDS-PAGE gel and then electroblotted onto a nitrocellulose membrane. The
membrane was blocked with 5% non-fat milk in TBST bu↵er (4 mM Tris base saline containing 0.1%
Tween-20, pH 7.5) for 1 h at RT, and then incubated with primary antibody anti-heat shock protein 70
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(Hsp70, 1:1000 dilution, ab2787 Abcam, RRID:AB_303300, Cambridge, UK), anti-cleaved caspase 3
(1:500 dilution, ab32042, RRID:AB_725947, Abcam, Cambridge, UK), anti-caspase 3 (1:500 dilution, 8G10,
RRID:AB_2069872, Cell Signaling Technology, Danvers, USA), anti-LC3 I/II (1:1000 dilution, 12741s,
RRID:AB_2617131, Cell Signaling Technology, Danvers, USA), and anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (1:5000 dilution, sc-365062, RRID:AB_10847862, Santa Cruz Biotechnology,
Dallas, USA) overnight at 4  C. After washing three times with TBST bu↵er, the membrane was
incubated with a secondary antibody (1:2000 dilution, Santa Cruz Biotechnology, USA) for 1 h at RT.
Then, signals were developed by the enhanced chemiluminescence (ECL) kit (Bio-Rad Laboratories,
Hercules, USA). Protein expression was quantified by the Fusion Pulse TS device (Vilber Lourmat,
Oberschwaben, Germany).
2.9. Fluorescence Microscopy with Acridine Orange Staining
Acidic vesicular organelles (AVOs) are autolysosomes and autophagosomes and can be measured
as markers of the late autophagic process [25,26]. To detect AVOs, cells were stained with acridine
orange (AO) according to published protocols [25,26]. AO is a lysosomotropic dye, its fluorescence
emission is pH dependent, green at neutral pH and bright yellow to red within acidic organelles [25,26].
SH-SY5Y cells were seeded into ibiTreat µ-Slide (Vitaris, Baar, Switzerland) and exposed to 1000 µM of
the synthetic methcathinones for 24 h at 37  C or 40.5  C. Then, the cell culture medium was replaced
by AO staining solution (0.5 µg/mL acridine orange in culture medium), and the µ-Slide was incubated
for 20 min at 37  C with light protection. The samples were rinsed three times with pre-warmed
medium and pictures were acquired by an Olympus IX83 microscope (Olympus, Shinjuku, Japan).
2.10. Flow Cytometry with Acridine Orange Staining
To quantify the formation of AVOs, we detected the intensity of AO fluorescence by flow cytometry.
AVOs stained with AO emit red fluorescence (FL3-A, 690/50 nm BP); the increase in the intensity of red
fluorescence (AO+ events) is proportional to the volume and number of AVOs [25,26]. SH-SY5Y cells
were seeded into a 48-well plate at a density of 200,000 cells per well and left to grow overnight. Cells
were treated with MC, 4-CMC, and 4-MMC at 1000 and 2000 µM, and MDMA at 500 and 1000 µM,
for 24 h, at 37 or 40.5  C. On the day of measurement, SH-SY5Y cells were transferred and pelleted
into a V-well plate, then washed twice with PBS. Afterwards, the cells were incubated with 100 µL
of AO staining solution (0.5 µg/mL in PBS) for 20 min at 37  C with light protection. SH-SY5Y cells
were analyzed with a CytoFLEX flow cytometer (Beckman Coulter, IN, USA). For the flow cytometry
gating strategy, singlets were first identified by an FSC-A/FSC-H gate, and then by an FSC-A/SSC-A
gate. AO+ cells were identified in an SSC-A/FL3-A dot plot, in comparison to DMSO 0.1%-treated cells
(control). Results were analyzed using the FlowJo software (Tree Star, Ashland, OR, USA).
2.11. Statistics
Experimental data are presented as the mean ± SEM of at least five independent experiments.
Statistical comparisons were performed with one-way ANOVA followed by t-tests. Statistical
significance was considered at P  0.05. GraphPad Prism 8.3.0 (RRID:SCR_002798) (GraphPad
Software, La Jolla, CA, USA) was used for all statistical analyses.
3. Results
3.1. Cell Membrane Integrity and ATP Content
In order to obtain an overview of the e↵ect of hyperthermia on amphetamine- and
methcathinone-induced neurotoxicity, we first determined the release of AK and the intracellular
ATP content in SH-SY5Y after 24 h of drug exposure under normothermic (37  C) and hyperthermic
conditions (40.5  C). AK release is commonly used as a marker of cell membrane integrity, whereas
the intracellular ATP content represents a marker of energy metabolism. SH-SY5Y cells were exposed
Results	
86	
  
Cells 2020, 9, 965 6 of 17
to increasing concentrations of amphetamine, 4-fluoroamphetamine (4-FA), 4-chloroamphetamine
(PCA), methcathinone (MC), 4-fluoromethcathinone (4-FMC), 4-chloromethcathinone (4-CMC), and
4-methylmethcathinone (4-MMC) (see Figure S1 for chemical structures). MDMA was also included
due its widespread use and its known e↵ects on body temperature.
As shown in Figure 1 for methcathinones and MDMA and in Figure S2 for the amphetamines,
all of these compounds were membrane toxic and decreased the intracellular ATP content in a
concentration-dependent manner. Exceptions wereMC and 4-FMC, which did not show any significant
toxicity up to 2000 µM (Figure 1). 4-FA and PCA were membrane toxic starting at 1000 and 500 µM,
respectively, at both temperatures investigated (Figure S2A), whereas 4-CMC, 4-MMC, and MDMA
were significantly more toxic at 40.5  C, with membrane toxicity starting at 1000 µM at this temperature
(Figure 1A).
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Figure 1. (A) Plasma me brane integr and (B) intracellular ATP content assessed in SH-SY5Y
cells after 24 h of exposure at 37 and 40.5  C to m thcathinone (MC), 4-fluoromethcathinone
(4-FMC), 4-chloromethcathinone (4-CMC), 4-methylmethcathinone (4-MMC) (200-2000 µM), and
3,4-methylenedioxymethamphetamine (MDMA) (500 and 1000 µM). Dimethyl sulfoxide (DMSO) and
Triton X were used as negative and positive controls, respectively. Data are expressed relative to the
DMSO contr l as the mean ± SEM of eight independ nt experiments. Statistical comparisons were
performed with on -way ANOVA follow d by t-tests (*P  0.05 versus control at the same temperature;
#P  0.05 versus the same concentration at a di↵erent temperature).
The intracellular ATP content in SH-SY5Y cells started to decrease at 2000 µM for 4-FA, 4-CMC,
and 4-MMC, and at 1000 µM for MDMA at normothermic conditions, whereas at 40.5  C, it started to
decrease at 2000 µM for amphetamine; 1000 µM for 4-FA, MDMA, and 4-MMC; at 200 µM for PCA; and
at 500 µM for 4-CMC (Figure 1B and Figure S2B). 4-FA, 4-CMC, 4-MMC, and MDMAwere significantly
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more toxic under hyperthermic conditions (Figure 1B and Figure S2B), in line with the findings of the
AK assessment experiments. Moreover, the drugs investigated showed a more pronounced toxicity
regarding the decrease in the intracellular ATP content when compared to membrane toxicity, a pattern
suggesting mitochondrial toxicity (Table S1).
Based on these first screenings, we decided to investigate the e↵ect of hyperthermia on the
neurotoxicity associated with the synthetic methcathinones MC, 4-CMC, and 4-MMC in more detail.
3.2. Mitochondrial Membrane Potential
In order to understand the mechanism of temperature-increased mitochondrial toxicity, we
determined the D m by staining SH-SY55 cells with the JC-10 dye [21]. Our data indicated that MC
did not change the D m significantly up to 2000 µM (Figure S3A). Similarly, MDMA was associated
with a numeric drop in the D m but without reaching statistical significance (Figure S3D). In contrast,
4-CMC and 4-MMC decreased the D m in a concentration-dependent manner at both temperature
conditions (Figure S3B and S3C), reaching statistical significance at 2000 and 1000 µM, respectively.
In contrast to AK release and ATP depletion, the D m did not show a more accentuated decrease at
40.5  C compared to 37  C.
3.3. Mitochondrial Oxygen Consumption
The observed decrease in intracellular ATP and D m could be caused by impaired mitochondrial
function. We therefore assessed the oxygen consumption rate (OCR) by exposing SH-SY5Y cells for
24 h at 37 and 40.5  C to the test compounds using a Seahorse XF96 analyzer. While MC was not toxic,
4-CMC (1000 µM), 4-MMC (1000 µM), and MDMA (500 µM) significantly decreased mitochondrial
basal and FCCP-stimulated respiration at 37  C (Figure 2). In comparison, at 40.5  C, all compounds
investigated started to be toxic already at 200 µM for both basal and FCCP-stimulated respiration
(Figure 2). We also recorded the leak respiration, which is the cellular uptake of oxygen in the presence
of the F1F0-ATP synthase inhibitor oligomycin. An increase in the leak respiration would indicate
uncoupling of oxidative phosphorylation. Since none of the compounds investigated stimulated leak
respiration, we can exclude uncoupling as a reason for the observed decrease in D m.Cells 2020, 9, x FOR PEER REVIEW 8 of 18 
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Figure 2. Oxygen consumption rate of S - 5 cells at 37 and 40.5  C expressed as basal, leak, and
maximal respiration. SH-SY5Y cell e for 24 h to (A,B) MC, (C,D) 4-CMC (E,F) 4- MC,
and (G,H) MDMA. Dat re xpres ed as mean ± i t i dependent experiments. S a stical
comparisons wer performed with one-way ANOVA followed by t-test (*P  0. 5 versus control at he
sam te perature; #P  0.05 versus the same con e tra ion at di↵erent temperature).
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In contrast to the e↵ect on the mitochondrial membrane potential, these data showed that
hyperthermic conditions clearly increased the mitochondrial toxicity of MC, 4-CMC, 4-MMC,
and MDMA. Furthermore, halogenation and methylation in the p-position increased the toxicity
of the methcathinones in comparison to hydrogen in this position.
3.4. Mitochondrial Superoxide Production
To further investigate the potential involvement of mitochondria in the observed toxicity, we
determined the mitochondrial ROS production. The inhibition of complex I and III of the electron
transport chain can increase the production of mitochondrial superoxide [27,28]. Mitochondrial ROS
were measured in SH-SY5Y cells exposed to methcathinones for 24 h at 37 and at 40.5  C. Concerning
normothermic conditions, only 4-CMC showed a significant increase of the mitochondrial ROS content,
which started at 2000 µM. At 40.5  C, the superoxide anion content increased significantly starting at
2000 µM for MC, and at 1000 µM for 4-CMC, 4-MMC, and MDMA (Figure 3).
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Figure 3. Mitochondrial superoxide production in SH-SY5Y cells at 37 and 40.5  C after 24 h of exposure
to MC, 4-CMC, 4-MMC (200–2000 µM), and MDMA (500 and 1000 µM). DMSO and amiodarone were
used as negative and positive controls, respectively. Data are expressed relative to DMSO control
as mean ± SEM of six independent experiments run in quadruplicate. Statistical comparisons were
performed with one-way ANOVA followed by t-tests (*P  0.05 versus control at the same temperature;
#P  0.05 versus the same concentration at a di↵erent temperature).
3.5. Cell Death Mechanisms
Inhibition of oxidative phosphorylationwith a decrease in the cellularATP content and intracellular
accumulation of ROS could initiate cell death mechanisms, such as apoptosis and/or necrosis [29].
To clarify whether hyperthermia can a↵ect such events in drug-treated SH-SY5Y cells, we analyzed the
proportion of apoptotic and necrotic cells after treatment with test compounds at 37 and 40.5  C for
6 and 24 h.
As expected, H2O2 at 0.5 µM increased the number of apoptotic and necrotic cells at both
temperatures (Figure 4A). At 37  C, after 6 h of incubation, 4-CMC increased the percentage of
apoptotic cells significantly, starting at 1000 µM (Figure 4A). In comparison, the other compounds
tested increased the percentage of apoptotic cells only numerically, without reaching statistical
significance. 4-CMC and 4-MMC increased the percentage of necrotic cells starting at 1000 and 2000 µM,
respectively, and MDMA starting at 1000 µM. Similar results were obtained for caspase 3 activation at
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37  C (Figure 4B). 4-CMC and 4-MMC increased caspase 3 cleavage starting at 1000 µM, whereas the
other compounds tested increased caspase 3 cleavage only numerically. In comparison, at 40.5  C,
the e↵ect of the compounds investigated on the percentage of apoptotic cells (Figure 4A) and caspase
3 cleavage (Figure 4B) was less accentuated than at 37  C. 4-CMC induced apoptosis, necrosis, and
caspase 3 cleavage at 2000 µM, whereas the other compounds were not associated with significant
increases in the induction of apoptosis, necrosis, or caspase 3 cleavage up to 2000 µM. After 24 h of
incubation at 37  C, none of the substances tested induced apoptosis, but 4-CMC and 4-MMC induced
necrosis starting at 2000 µM (Figure S4). At 40.5  C, the picture was not di↵erent from 37  C, but the
extent of necrosis was numerically more accentuated.Cells 2020, 9, x FOR PEER REVIEW 10 of 18 
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Figure 4. Mechanisms of cell death after 6 h of exposure at 37 and 40.5  C to MC, 4-CMC, 4-MMC
(1000 and 2000 µM), and MDMA (500 and 1000 µM). DMSO and H2O2 were used as negative and
positive controls, respectively. (A) Percentage of necrotic and apoptotic cells. (B) Activation of caspase
3. Data are expressed as mean ± SEM of six independent experiments. Statistical comparisons were
performed with one-way ANOVA followed by t-tests (*P  0.05 versus control at the same temperature;
#P  0.05 versus the same concentration at a di↵erent temperature).
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The data suggested a shift from apoptosis to necrosis at the higher temperature and with longer
incubation. In order to obtain a better understanding of this shift, we also determined the AK release
and ATP content in the presence of the methcathinone derivatives after 6 h of incubation (Figure S5).
The ATP content dropped, and the AK release increased only at the highest 4-CMC concentrations at
both temperatures investigated, which is compatible with the increase in cell necrosis observed with
this compound.
To better understand the e↵ects of hyperthermia on the cell death pathways, we measured the
expression of Hsp70 protein in SH-SY5Y cells after 6 h of exposure to the synthetic methcathinones.
Hsp70 are a family of proteins, which protect the cells from stress by helping cellular proteins to retain
their native conformation or to regain their function after misfolding due to an increased temperature.
Hsp70 proteins are usually upregulated by heat stress and toxic chemicals [30]. As expected,
Hsp70 expression was significantly increased at 40.5  C compared to 37  C for all compounds tested as
well as for DMSO-treated control cells (Figure 5). In comparison to control incubations, the compounds
investigated did not influence Hsp70 expression at 37 or 40.5  C.Cells 2020, 9, x FOR PEER REVIEW 11 of 18 
 
Figure 5. Expression of 70 kilodalton heat shock protein (Hsp70) in SH-SY5Y cells after 6 h of exposure 
at 37 and 40.5 °C to MC, 4-CMC, 4-MMC (200–2000 μM), and MDMA (500 and 1000 μM). Data are 
expressed relative to the DMSO control as mean ± SEM of six independent experiments. Statistical 
comparisons were performed with one-way ANOVA followed by t-tests (#P ≤ 0.05 versus the same 
concentration at a different temperature). 
3.6. Detection of Autophagy 
Autophagy is a physiological catabolic process used by most cells to remove misfolded proteins 
or entire organelles in order to maintain proteo- and homeostasis. It is triggered mainly by starvation, 
cell insults, and DNA damage [31]. Hyperthermic conditions, exposure to mitochondrial toxicants, 
and cellular ROS accumulation can generate misfolded proteins, which can affect the cellular 
metabolism [32]. In order to explore whether hyperthermia and/or methcathinones can promote 
autophagy in SH-SY5Y cells, we analyzed the expression of autophagy-related protein microtubule-
associated protein 1A/1B-light chain 3 (LC3) by Western blots [25]. LC3 is a component of the 
autophagosome membranes in mammalian cells, and it is a validated marker for the assessment of 
early autophagy [33]. During the first phase of autophagy, the cytosolic form of LC3 (LC3 I) is cleaved 
and conjugated with phosphatidylethanolamine to form LC3 II, which is then translocated into 
autophagosome membranes. An increase in the LC3 II/LC3 I ratio therefore reflects autophagosome 
formation [34]. SH-SY5Y cells were exposed at 37 and 40.5 °C to MC, 4-CMC, 4-MMC (1000 and 2000 
μM), and MDMA (500 and 1000 μM). After 24 h of incubation at 37 °C, all test compounds showed a 
concentration-dependent increase in the LC3 II/LC3 I ratio compared to control conditions, which 
reached statistical significance for 2000 μM 4-CMC and for 2000 μM 4-MMC (Figure 6). Under 
hyperthermic conditions, the effect of the test compounds on the LC3 II/LC3 I ratio was similar but 
more accentuated for 4-CMC and 4-MMC as compared to 37 °C. 
D
M
SO
 0
.1
%
 1
00
0 
µM
 
20
00
 µ
M
 
 1
00
0 
µM
 
20
00
 µ
M
 
 1
00
0 
µM
 
20
00
 µ
M
 
50
0 
µM
10
00
 µ
M
D
M
SO
 0
.1
%
 1
00
0 
µM
 
20
00
 µ
M
 
 1
00
0 
µM
 
20
00
 µ
M
 
 1
00
0 
µM
 
20
00
 µ
M
 
50
0 
µM
10
00
 µ
M
0
2
4
6
8
H
sp
70
 e
xp
re
ss
io
n
(fo
ld
 c
ha
ng
e 
to
 D
M
SO
 C
trl
)
40.5°C
37°C
MC 4-CMC 4-MMC MDMA MC 4-CMC 4-MMC MDMA
#
#
#
#
#
#
#
#
#
70 kDa
D
M
SO
0.
1%
10
0 0
 μ
M
 
2 0
00
 μ
M
 
Hsp70
GADPH 38 kDa
10
00
 μ
M
 
20
0 0
 μ
M
 
1 0
0 0
 μ
M
 
2 0
00
 μ
M
 
5 0
0  
μM
 
1 0
0 0
 μ
M
 
MC 4-CMC 4-MMC MDMA
D
M
SO
0.
1%
1 0
00
 μ
M
 
20
00
 μ
M
 
1 0
00
 μ
M
 
2 0
00
 μ
M
 
1 0
0 0
 μ
M
 
2 0
00
 μ
M
 
50
0  
μM
 
1 0
00
 μ
M
 
MC 4-CMC 4-MMC MDMA
37 °C 40.5 °C
Figure 5. Expression of 70 kilodalton heat shock protein (Hsp70) in SH-SY5Y cells after 6 h of exposure
at 37 and 40.5  C to MC, 4-CMC, 4-MMC (200–2000 µM), and MDMA (500 and 1000 µM). Data are
expressed relative to the DMSO control as mean ± SEM of six independent experiments. Statistical
comparisons were performed with one-way ANOVA followed by t-tests (#P  0.05 versus the same
concentration at a di↵erent temperature).
3.6. Detection of Autophagy
Autophagy is a physiological catabolic process used by most cells to remove misfolded proteins or
entire organelles in order to maintain proteo- and h meostasis. It is triggered mainly by starvation, cell
insults, and DNA damage [31]. Hyperth mic conditions, exposure to mitochondrial toxic nts, and
cellularROSaccumulation cangeneratemisfolded rot ins, which can a↵ect the cellul rmetabolism [32].
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In order to explore whether hyperthermia and/or methcathinones can promote autophagy in SH-SY5Y
cells, we analyzed the expression of autophagy-related protein microtubule-associated protein
1A/1B-light chain 3 (LC3) by Western blots [25]. LC3 is a component of the autophagosome membranes
in mammalian cells, and it is a validated marker for the assessment of early autophagy [33]. During
the first phase of autophagy, the cytosolic form of LC3 (LC3 I) is cleaved and conjugated with
phosphatidylethanolamine to form LC3 II, which is then translocated into autophagosome membranes.
An increase in the LC3 II/LC3 I ratio therefore reflects autophagosome formation [34]. SH-SY5Y cells
were exposed at 37 and 40.5  C to MC, 4-CMC, 4-MMC (1000 and 2000 µM), and MDMA (500 and
1000 µM). After 24 h of incubation at 37  C, all test compounds showed a concentration-dependent
increase in the LC3 II/LC3 I ratio compared to control conditions, which reached statistical significance
for 2000 µM 4-CMC and for 2000 µM 4-MMC (Figure 6). Under hyperthermic conditions, the e↵ect of
the test compounds on the LC3 II/LC3 I ratio was similar but more accentuated for 4-CMC and 4-MMC
as compared to 37  C.
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Figure 6. Protein expression of microtubule-associated protein 1A/1B-light chain 3 (LC3) I and LC3 II
in SH-SY5Y cells after 24 h of exposure at 37 and 40.5  C to (A) C, 4-C C, 4- C (200–2000 µ ),
and MDMA (500 and 1000 µM) and (B) in the presence of the autophagy inhibitors concanamycin
A (100 nM) and bafilomycin A (100 nM). Data are expressed as the ratio of LC3 II/LC3 I relative to
the DMSO control of six independent experiments. Statistical comparisons were performed with
one-way ANOVA followed by paired t-test (*P  0.05 versus DMSO control at the same temperature;
# P  0.05 versus the same concentration at a di↵erent temperature; §P  0.05 versus incubations
containing 4-CMC or 4-MMC without concanamycin A or bafilomycin A).
In order to investigate whether the observed increase in the LC3 II/LC3 I ratio in the presence
of 4-CMC and 4-MMC was due to increased phagosome formation or decreased degradation, we
investigated the e↵ect of the two autophagy inhibitors concanamycin A and bafilomycin A on the
LC3 II/LC3 I ratio. Concanamycin A and bafilomycin A impair the fusion of autophagosomes and
lysosomes by inhibiting the vacuolar H+ ATPase and therefore the acidification of organelles, which
increases LC3 II expression [24]. As shown in Figure 6A, in the absence of concanamycin A and
bafilomycin A, treatment with 2000 µM 4-CMC or 4-MMC significantly increased the LC3 II/LC3 I ratio
both at 37 and 40.5  C compared to control incubations, with 40.5  C being more e↵ective than 37  C.
As shown in Figure 6B, as expected, concanamycin A and bafilomycin A increased the LC3 II/LC3 I
ratio at both temperatures compared to the DMSO control. At 37  C, concanamycin A and bafilomycin
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A increased the LC3 II/LC3 I ratio in the presence of 4-CMC or 4-MMC compared to the respective
control incubations (2000 µM 4-CMC or 4-MMC). At 40.5  C, this e↵ect was less prominent and did
not reach statistical significance. Importantly, the LC3 II/LC3 I ratios of incubations containing only
concanamycin A or bafilomycin A and of incubations containing concanamycin A or bafilomycin A in
combination with 4-CMC or 4-MMC were not di↵erent at both temperatures. Since concanamycin A
and bafilomycin A block autosome degradation, the LC3 II/LC3 I ratio in the presence of these inhibitors
reflects autophagosome formation, which was obviously not di↵erent between incubations containing
only concanamycin A or bafilomycin A and incubations containing concanamycin A or bafilomycin A
in combination with 4-CMC or 4-MMC. The results therefore suggest that the observed increase in the
LC3 II/LC3 I ratio in the presence of 4-CMC and 4-MMC reflects impaired autophagosome degradation
and not formation.
To further study the autophagy,weassessed the formationof acidic vesicular organelles (AVOs) [25],
which is a hallmark of late autophagy [26]. Microscopic analysis of SH-SY5Y cells exposed for 24 h
at 37 and 40.5  C to MC, 4-CMC, and 4-MMC (1000 µM) showed an accumulation of AO dye within
acidic compartments (Figure 7A). All the tested drugs increased the formation and size of the AVOs at
both temperature conditions. Moreover, 4-CMC and 4-MMC at hyperthermic conditions a↵ected the
morphology of the cells, with a reduction of neuritic processes (Figure 7A). To confirm the e↵ect of the
investigated compounds on AVO formation, SH-SY5Y cells were exposed for 24 h at 37 and 40.5  C to
MC and 4-MMC (1000 and 2000 µM) and to 4-CMC (500 and 1000 µM) and AVOs were quantified by
flow cytometry (Figure 7B). At 37  C, 4-CMC and 4-MMC showed a significantly increased percentage
of AO+ cells at 1000 µM compared to control incubations. Compared to 37  C, exposure to 4-CMC
and 4-MMC at 40.5  C was associated with more AVO formation (Figure 7B), and 4-CMC significantly
increased AVO abundance at 40.5  C already at 500 µM.
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Figure 7. (A) Fluorescence microscopy visualization of acidic vesicular organelles (AVOs) stained
with acridine orange (AO). SH-SY5Y cells were exposed to MC, 4-CMC, and 4-MMC (1000 µM) for
24 h at 37 and 40.5  C. Scale bar 20 µm, magnification 60⇥. (B) Flow cytometric quantification of
AVOs. SH-SY5Y cells were exposed to MC (1000 and 2000 µM), 4-CMC (500 and 1000 µM), and
4-MMC (1000 and 2000 µM) for 24 h at 37 and 40.5  C. Data are expressed as mean ± SEM of five
independent experiments. Statistical comparisons were performed with one-way ANOVA followed by
t-tests (* P  0.05 versus control at the same temperature; #P  0.05 versus the same concentration at a
di↵erent temperature).
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4. Discussion
Barbosa et al. [17] have shown in aprevious study that the toxicity of ecstasy and ecstasymetabolites
on di↵erentiated SH-SY5Y cells is increased at hyperthermic (40  C) compared to normothermic (37  C)
conditions. Similarly, in the present study, we demonstrated that hyperthermic conditions increase the
cytotoxicity of methcathinones by inducing apoptotic and necrotic cell death. The loss in cell membrane
integrity was preceded by a decrease in cellular ATP content, a typical feature of mitochondrial
toxicants [21,35]. We could confirm our previous investigations on the hepatocellular and muscle
toxicity observed with these drugs [27,36].
The choice of the higher temperature was based on the study of Barbosa et al. [17] and on clinical
reports suggesting that body temperatures  40  C are associated with severe complications, such as
intravascular coagulation, rhabdomyolysis, renal and multiorgan failure, and even death, in patients
having ingested ecstasy or other psychostimulants [9,10].
The mitochondrial toxicity of the methcathinones studied was confirmed by the investigation of
their e↵ect on mitochondrial respiration. For all compounds studied, a prominent reduction of basal
and FCCP-induced respiration was observed at 40.5  C compared to 37  C. Mitochondrial toxicants
that reduce the OCR, which indicates an impairment of the electron transport chain, can result in a
decrease in D m and an increase in mitochondrial generation of ROS [37], which we observed in the
current study. In agreement with the results of the current study, previous in vitro investigations have
shown that synthetic methcathinones increase the production of ROS and nitrogen reactive species
in human dopaminergic SH-SY5Y cells [25]. Moreover, animal studies revealed that methcathinones
increase the expression of the antioxidant enzymes superoxide dismutase, catalase, and glutathione
peroxidase in response to ROS accumulation [38].
Mitochondrial impairment and ROS accumulation can lead to the opening of the mitochondrial
permeability transition pore (mPTP), and subsequently to the release of cytochrome c into the cytoplasm,
which is followed by caspase activation and apoptosis [39,40]. In our study, exposure to 4-CMC
and 4-MMC already induced apoptosis and/or necrosis at both temperature conditions after 6 h
of incubation.
Surprisingly, after 6 h of incubation, the compounds investigated were more toxic at normothermic
conditions than under hyperthermic conditions, whereas, after 24 h, the temperature shift from 37 to
40.5  C clearly increased the toxicity of the methcathinones studied. These findings suggested the
induction of defensive mechanisms that could protect the cells during the first hours of the caloric
insult. We therefore determined the expression of Hsp70 proteins, which are molecular chaperones
synthesized in response to a heat shock [41]. As shown in Figure 5, hyperthermic conditions increased
the expression of Hsp70 proteins, independently of the exposure to the compounds tested. Already after
6 h at 40.5  C, the expression of Hsp70 was significantly higher than under normothermic conditions.
These proteins, which assist in the folding and assembly of newly synthesized proteins as well as
refolding of misfolded and aggregated proteins, act in an ATP-controlled fashion [42]. Importantly,
Hsp70 proteins can inhibit mitochondrial cytochrome c release, apoptosome formation, and caspase
activation [43,44]. The results of the current study suggest that at the 6-h time point, the induction of
HSP70 partially prevented not only the cellular damage induced by heat but also the toxic insult by the
methcathinones investigated.
However, because of the ongoing ROS-induced protein and organelle damage and the associated
decrease in the cellular ATP content, this defensive system may be not able to counteract the cellular
insults. Autophagy is an additional defensive mechanism, which may be stimulated under these
conditions. In support of this assumption, it has been shown that 3-fluoromethcathinone (3-FMC),
another synthetic methcathinone, activates autophagy in the neuronal cell line HT22 [45]. Autophagy
is an evolutionarily conserved process, which plays a pivotal role in maintaining the viability of
eukaryotic organisms by regulating the intracellular balance between anabolism and catabolism [46].
Autophagy is activated as a protective mechanism when cells are not able to respond to nutrient stress,
the accumulation of misfolded proteins, and/or organelle damage [47]. In our investigations, LC3 II,
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an early marker of autophagy [48], was overexpressed in SH-SY5Y cells after exposure to 4-CMC
under both temperature conditions. Furthermore, we demonstrated the stimulation of autophagy
directly by the visualization of acidic vesicular organelles (AVOs) in SH-SY5Y cells exposed to 4-CMC
and 4-MMC, which is a marker of late autophagy. Similar to the induction of HSP70, hyperthermic
conditions also increased the formation of AVOs, suggesting that the activation of the cellular defense
systems is tightly coordinated.
In comparison to their pharmacological activity, which is observed in the high nanomolar
to micromolar range depending on the compound and the pharmacological e↵ect considered [49],
cytotoxicitywas detected at higher concentrations in the current study. For 4-CMC, blood concentrations
reached approximately 1 micromolar with non-toxic pharmacological doses and up to 10 micromolar in
patients with intoxications [50]. In the current study, we started to see an impairment of cellular oxygen
uptake at 200 micromolar for MC, 4-CMC, and 4-MMC. A possible explanation for this discrepancy
between pharmacological activity and in vitro toxicity may be that the cell lines used in the current
study may be less sensitive to toxicants than primary cells. This has, for instance, been shown for
hepatotoxicants, which are typically less toxic for human hepatocyte cell lines than for primary human
hepatocytes [51,52]. Furthermore, patients presenting with neurotoxicity have usually ingested doses
higher than the pharmacological doses of these compounds and may have ingested additional toxic
drugs and/or alcohol. Finally, the brain/plasma concentration ratio for 4-MMC is >1, indicating that
the drug penetrates the blood–brain barrier easily and that the concentration reached in the brain is
higher than in plasma [53].
Interestingly, many studies have shown a link between autophagy and neurodegenerative
diseases [31,54,55]. A prevalent pathological feature of many neurodegenerative diseases, such as
Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington disease (HD), is in fact the
aggregation of misfolded proteins, which may result from the production of defective proteins and/or
impaired function of the protein quality control systems. Our studies suggest that repetitive ingestion
of neurotoxic drugs, such as methcathinones, and other neurotoxic neurostimulants may aggravate or
even provoke such conditions.
5. Conclusions
In conclusion, 4-CMC and 4-MMC are mitochondrial toxicants whose toxicity is increased by
shifting the temperature from 37 to 40.5  C. SH-SY5Y cells exposed to 40.5  C activate cellular defense
mechanisms, such as the expression of Hsp70 proteins, which can partially prevent early apoptosis and
necrosis. With time, the activation of additional defense mechanisms, such as autophagy, is necessary to
prevent cell dysfunction and cell death. Mitochondrial toxicity, which is accentuated by hyperthermia,
represents an important mechanism of the neural toxicity of these compounds.
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Abuse of psychostimulant drugs is becoming a more and more serious problem in the 
world [251]. Clinical case reports have shown that the abuse of psychostimulant drugs can 
result in significant organ damage in users, affecting the liver, muscle and/or brain [79, 124, 
252-257]. Another important acute side effect due to the use of psychostimulant drugs is 
hyperthermia, which is a contributing factor to several acute complications and which can 
lead to a fatal outcome [243, 246]. Therefore, we aimed to assess the toxicological 
mechanisms of psychostimulant drugs in vitro (muscle, liver and neuronal cells), and to 
assess how hyperthermic conditions may affect the toxicity of these drugs in neuron cells. 
In our studies, we used concentrations of drugs ranging from 100 µM to 2000 µM. In 
some fatality cases, the plasma concentrations of these NPS reached 22.00 mg/L (~125 µM, 
4-MMC), 18.50 mg/L (105 µM, MDMA), 3.13 mg/L (17.78 µM, methylone), 0.64 mg/L 
(~3.64 µM, α-PVP), 0.30 mg/L (~1.70 µM, 3-MMC), 0.17 mg/L (~0.97 µM, MDPV) [52, 
247, 258-260]. These concentrations are quite lower than the highest drug concentration used 
by us in vitro (2000 µM). There are two reasons for using high concentrations: (1) high 
concentrations were used to elucidate the molecular toxicological mechanisms of these drugs, 
since in vivo their effects can be observed only at higher concentrations than in vivo [73]. (2) 
users often use these drugs for a long time, in this regard, in our experimental settings we 
used higher concentrations for shorter exposure time, a common research method in vitro 
[261]. It has also to be taken into account that we used cell lines for our investigations, which 
may be less sensitive than primary cells. Furthermore, only serum concentrations have been 
determined (or post mortem blood concentrations), which may not reflect the concentrations 
in the brain. 
1. Effect of para-halogenation on amphetamines and cathinones 
Our current studies suggested that the toxicity rank order of these para-halogenated 
amphetamines and methcathinones is the following: Cl >F >H. According to the IC50 values 
of membrane integrity in HepG2 cells, and undifferentiated and differentiated SH-SY5Y cells, 
we found that PCA impairs the cell membrane at lower concentrations than the other 
investigated drugs, followed by 4-FA. Amphetamine showed the highest IC50. Moreover, the 
results in these three cell types have shown that fluorinated and chlorinated forms of 
amphetamine can induce mitochondrial dysfunction, however, amphetamine showed 
mitochondrial toxicity only in HepG2 cells. A similar result for the para-halogenated forms 
of cathinone was observed. 4-CMC can cause cell membrane integrity loss in HepG2 cells, 
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undifferentiated and differentiated SH-SY5Y cells, while no effect was observed for 4-FMC 
and MC at concentrations up to 2 mM. Besides that, only 4-CMC was a mitochondrial 
toxicant among all the para-halogenated cathinones. Taken together, both p-F and p-Cl 
increase the cytotoxicity of amphetamine and methcathinone. 
This finding could be explained by the data of Fuller et al. [45]. para-Halogenated 
amphetamine derivatives are more lipophilic, they show longer half-life, and also are more 
potent inhibitors of the monoamine oxidase, again following the order Cl >F >H. 
In addition to the toxicity rank (Cl >F >H), para-halogenation has other effects on 
drugs. Based on our pharmacological experiments, para-halogenated phenylethylamines may 
enhance serotonergic effects [262]. One feasible explanation is that the para-halogenation 
prevents para-hydroxylation, and then prolongs the half-life of the compound, enhancing its 
clinical effects [263]. For para-halogenated amphetamines and methcathinones, inhibition of 
norepinephrine uptake was observed at sub-micromolar concentrations. Other authors 
reported that the para-halogenation reduces the selectivity towards DAT over SERT [19, 
264-266]. PCA and 4-CMC were considered to reduce the selectivity towards SERT and 
DAT in a similar manner as para-methylation [267]. The inhibition of NET and DAT 
correlated with human effective doses, while SERT inhibition was inversely correlated with 
human effective doses [268], suggesting that the clinical effects of halogenation are low. 
However, the highly potent serotonergic activity and fairly strong dopaminergic activity can 
be a possible explanation of the severe serotonergic neurotoxicity of PCA [269]. Furthermore, 
it has been reported that amphetamines can enhance users’ risk of developing Parkinson's 
syndrome 1.5 to 3 times [270, 271]. Parkinson's syndrome develops due to the loss of 
dopaminergic neurons in the nigrostriatal system, which may be induced by mitochondrial 
damage [272]. As a result, current research suggests that the halogenation of stimulant drugs 
may increase this risk. If confirmed, this will be an important finding which could have an 
impact on the use of these halogenated compounds. 
2. Mitochondrial mechanism of toxicity 
The mechanism beyond the organ damage induced by NPS is not completely clear 
yet [273]. Mitochondria are known as energy generators for cells, and as well as a primary 
target in drug toxicity, due to their structural and functional characteristics	[164, 274]. 
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In our current studies, we found that amphetamine, 4-FA and PCA are among all the 
amphetamines tested in vitro mitochondrial toxicants. Moreover, high concentrations of 4-FA 
can trigger apoptosis in HepG2 cells, and PCA can induce apoptosis in undifferentiated and 
differentiated SH-SY5Y cells. For the investigated synthetic cathinones, 4-CMC can cause 
mitochondrial dysfunction and apoptosis in HepG2 cells, undifferentiated and differentiated 
SH-SY5Y cells. 4-MMC showed as well mitochondrial toxicity in undifferentiated SH-SY5Y 
cells. Besides that, α-PVP and naphyrone were also strong toxicants in C2C12 myoblasts, 
affecting their mitochondrial function. In more detail, a decrease in the ATP content prior to 
cell membrane integrity loss after drug exposure suggests that the mitochondria are a target 
of these drugs [275, 276]. We found that the IC50 values of ATP content decrease were lower 
than the IC50 values of membrane toxicity (MT) after amphetamine, 4-FA, PCA and 4-CMC 
exposure in HepG2 cells, and for α-PVP and naphyrone in C2C12 cells. This effect was 
observed for 4-FA, PCA, 4-MMC and 4-CMC in undifferentiated SH-SY5Y cells, as well for 
4-FA, PCA and 4-CMC in differentiated SH-SY5Y cells. It is known that the decrease of the 
cellular ATP content and the Δψm are considered as markers of the perturbation of 
mitochondria [277]. We found that a significant reduction of the Δψm at similar 
concentrations of the depletion of the cellular ATP, after 4-FA, PCA and 4-CMC exposure. 
Additionally, the decrease of cellular ATP and Δψm can be associated with the impairment 
and/or uncoupling of the mitochondrial respiratory chain [164]. In HepG2 cells, amphetamine 
decreased the basal respiratory capacity, whereas 4-FA, PCA and 4-CMC decreased both 
basal and maximal respiration. For C2C12 cells, α-PVP and naphyrone not only impaired 
basal respiratory capacity, but also decreased the maximal respiration at similar 
concentrations after treatment for 1 or 24 h. α-PVP and naphyrone impaired the activity of 
enzyme complexes of the ETC. α-PVP inhibited complex I, and naphyrone inhibited complex 
II. Our data in undifferentiated and differentiated SH-SY5Y cells demonstrated that PCA and 
4-CMC reduced basal and maximal respiration, while 4-MMC only impaired the basal 
respiratory capacity in undifferentiated SH-SY5Y cells. 4-CMC exposure resulted in decrease 
of the leak and maximal respiration at a lower concentration than 4-MMC in undifferentiated 
SH-SY5Y cells. This indicates that 4-CMC is slightly more toxic than 4-MMC [278]. 
It is well known that the neurotoxicity of amphetamines and synthetic cathinones can 
be linked with the accumulation of cellular ROS [79, 135, 273, 279-283]. Since the enzyme 
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complexes I and III of the ETC are potential sites for ROS formation, the increase in ROS 
levels may cause disruption of the mitochondrial respiratory chain, damage of various 
cellular components and result in mitochondrial toxicity [187, 284, 285]. 
Concentration-dependent increases in ROS were also observed after treatment with 
amphetamine, 4-FA, PCA and 4-CMC in HepG2 cells. PCA and 4-CMC promoted the ROS 
production in undifferentiated and differentiated SH-SY5Y cells, while 4-FA and 4-CMC 
increased the ROS level only in undifferentiated SH-SY5Y cells. In C2C12 cells, as 
expected, α-PVP and naphyrone led to an increase of mitochondrial ROS level. Additionally, 
the in vivo data shown by Naserzadeh et al. suggest that 4-MMC could promote 
mitochondrial ROS production and impair the outer mitochondrial membrane [286]. This 
result is consistent with our observations of 4-MMC. In conclusion, NPS-induced 
mitochondrial dysfunction is related to the inhibition of mitochondrial oxidative metabolism. 
Furthermore, the impairment of the cellular antioxidant response could contribute to the 
increase in ROS levels. These findings are in agreement with a recent report of Chen et al., 
showing the toxicity of amphetamines in a pulmonary artery model [124, 287]. 
The release of cytochrome c from mitochondria can trigger the activation of caspases, 
suggesting that ROS play an important role in apoptosis	[288]. We further investigated cell 
death mechanisms in HepG2 cells. As shown in our study, a concentration-dependent 
increase in apoptotic and necrotic cells appear after treatment with 4-FA. These observations 
are in accordance with the effect on the cellular ATP level [289]. The assessment of ATP 
content after PCA exposure showed a decrease in the ATP content at a lower concentration 
than for 4-FA and amphetamine. Treatment with 0.5 mM PCA resulted in almost complete 
depletion of ATP, indicating a large number of necrotic cells at this concentration. After 
treatment with 2 mM amphetamine and 4-FA, the amount of necrotic and apoptotic cells 
showed no significant difference from the control incubation. In undifferentiated and 
differentiated SH-SY5Y cells, PCA and 4-CMC also caused a large amount of ROS 
accumulation and further triggered apoptosis. In this regard, the generation of mitochondrial 
ROS can result in opening of the mitochondrial permeability transition pore (mPTP), which 
is linked to a drop of the mitochondrial membrane potential and the release of cytochrome c 
into the cytoplasm where it may activate the caspase pathway [207, 290]. Further studies 
supported this finding; we found that 4-CMC induce apoptosis via the activation of caspase 9 
and 3, the endogenous apoptotic pathway. 
 
Discussion	
104	
 
3. Non-mitochondrial mechanism of toxicity 
In addition to mitochondrial dysfunction, other mechanisms can decrease the cellular 
ATP content and lead to cytotoxicity. In our studies, a drop in the cellular ATP content was 
observed after methcathinone and 4-FMC exposure in HepG2 cells, while 3-MMC, MDPV 
and methylone resulted in cytotoxicity with a non-mitochondrial mechanism in C2C12 cells. 
Data generated in our studies demonstrated that methcathinone, 4-FMC, 3-MMC, 
MDPV and methylone could cause ATP depletion without impairing the function of the 
mitochondrial respiratory chain and the activity of enzyme complexes of the mitochondrial 
ETC. One possible reason why these drugs induced ATP depletion without detecting 
mitochondrial dysfunction is that when glucose is present in cells, ATP can also originate 
from glycolysis, which may be impaired by these drugs [291]. In addition, the IC50 values of 
impaired membrane integrity and ATP depletion are close, indicating that ATP depletion may 
be a secondary event after disrupting membrane integrity [291]. To our surprise, we also 
observed the increase of cellular ROS level for 3-MMC, MDPV and methylone, without 
impairment of the ETC. One of the possible reasons is that low expression of SOD2 results in 
low antioxidant capacity of C2C12 myoblasts and HepG2 cells [291, 292]. 
4. Effect of NPS on Different Cell Types 
In our studies, the concentrations of NPS used were much higher than the 
concentrations pharmacologically relevant (<50 µM). Exposure to pharmacological 
concentration of drugs in primary liver cells and HepG2 cells does not induce toxicity	[261]. 
It is possible that HepG2 cells are robust cell model with low level of transporter and enzyme 
expression [293], suggesting lower susceptibility to hepatotoxic toxicity than primary liver 
cells. Moreover, these NPS require active transport to enter cells in vivo, it is hard to simulate 
under experiment conditions in vitro due to the limited ability to diffuse across cell 
membranes [294]. In addition, these NPS can elevate temperature in vivo, the toxicity of 
these NPS may be underestimate in vitro	[123]. 
Of note, comparing the effects of NPS in undifferentiated and differentiated 
SH-SY5Y cells, most of the tested NPS have shown less toxicity in differentiated SH-SY5Y 
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cells. We can explain that due to cell differentiation, which may modulate the regulation of 
glycolysis and oxidative phosphorylation, affecting the way cells respond to 
toxicants-induced oxidative stress [282, 295-297]. Moreover, differentiated SH-SY5Y cells 
have stronger stimulation of mitochondrial respiration capacity with uncoupling and a higher 
bioenergetic reserve capacity [297], and differentiated cells may express more SOD enzymes 
compared to the undifferentiated SH-SY5Y cells [297]. 
For C2C12 cells, our data showed that naphyrone is a strong toxicant of the 
mitochondrial function, while MDPV and 4-MMC can cause cytotoxicity through a 
non-mitochondrial mechanism. Whereas in HepG2 cells naphyrone, MDPV and 4-MMC 
induced all mitochondrial toxicity by impairing the ETC [124]. These findings seem to point 
out that the mechanisms of NPS-induced toxicity may vary considerably within different 
organs. 
Taken together, our results in different cell lines show the following rank of 
sensitivity to NPS-induced mitochondrial toxicity: HepG2 cells <SH-SY5Y cells <C2C12 
cells. 
5. Hyperthermia 
Drug-induced hyperthermia can be caused by several factors. Most psychostimulant 
drugs can direct increase metabolic heat production and/or decrease heat dissipation [246, 
298]. Moreover, drug-induced serotonin syndrome and adrenergic receptor stimulation are 
also considered as important factors in hyperthermia [246]. MDMA is a very popular 
amphetamine, its use is associated with body temperature increase. There are three possible 
mechanisms of MDMA-induced hyperthermia. First, MDMA can cause serotonin release and 
result in a serotonin syndrome [299]. Second, the increase of dopamine release due to the 
interaction of MDMA with D1 receptors [300]. Third, the adrenergic receptor stimulation can 
lead to mitochondria uncoupling and vasoconstriction [246]. However, to date there are only 
few studies about the hyperthermia caused by other drugs. 
In order to evaluate the possible mechanism of NPS-induced hyperthermia, we 
explored the pharmacological effects of para-substituted amphetamines and methcathinones. 
They are monoamine transporter substrates [266], which can elevate the extracellular 
monoamine levels by reversing transporting transporters [301, 302]. This further results in 
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inhibition of monoamine uptake transport from the synaptic cleft. The para-halogenated 
amphetamines and methcathinones in our study interacted effectively with monoaminergic 
systems, which regulate body temperature in a variety of ways [303]. In our opinion, 
hyperthermia could be a possible manifestation of using these substances. 
To further investigate the role of hyperthermia on the neurotoxicity induced by these 
drugs, we first assess the cell membrane integrity of undifferentiated SH-SY5Y cells exposed 
to these substances at 37 °C or 40.5 °C. Our data demonstrated that high temperatures 
increased the cytotoxicity and mitochondrial impairment of the synthetic cathinones 4-CMC 
and 4-MMC. These results were further supported by the data on the mitochondrial 
respiration. Our results showed that methcathinone, 4-CMC and 4-MMC decreased MMP 
with a temperature-dependent effect and depleted OCR at low concentrations after incubation 
at 40.5 °C for 24 h, compared to 37 °C. The inhibition of the complexes of the ETC is likely 
to increase the production of ROS [304]. In in vivo studies, methcathinones can also increase 
ROS levels and expression of the antioxidant enzymes, superoxide dismutase, catalase, and 
glutathione peroxidase [305]. In our study, data of ROS production showed that 
methcathinone, 4-MMC, MDMA as well as low concentration of 4-CMC have significantly 
elevated the generation of ROS at hyperthermic conditions compared to normothermic 
conditions. It indicates that a possible reason for hyperthermia-enhanced neurotoxicity is the 
promotion of ROS production. Moreover, the collapse of the MMP and the accumulation of 
ROS can be associated with the opening of the mPTP and the initiation of apoptosis via the 
activation of caspases [306]. 
Apoptosis is a programmed form of cellular death, which is distinct from necrosis as 
it can occur under physiological and pathological conditions [307]. However, we observed 
that hyperthermia decreased apoptosis in cells exposed to drugs when compared to 37 °C 
condition. We tested the expression of Hsp 70, proteins that are considered the cellular 
defence system against the damage of hyperthermia, and we found that the expression of Hsp 
70 was significantly higher at 40.5 °C after 6 h drugs exposure compared with normothermic 
conditions. These results further supported that hyperthermia activates the Hsp 70 to avoid 
cell death mechanisms [308]. Furthermore, Hsp 70 proteins can also inhibit the activation 
caspases [309, 310]. These findings are consistent with our results on the activation of 
caspase 3. 
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However the accumulation of protein aggregates and ROS may reach a level where 
this defensive mechanism is not anymore able to act, consequently, autophagic cell death 
(ACD) may happen, as shown with 3-fluoromethcathinone (3-FMC) in the neuronal cell line 
HT22 [311]. In our studies, an enhancement of expression in the marker of early autophagy 
LC3 II was observed in undifferentiated SH-SY5Y cells after 4-CMC exposure at 
hyperthermic condition. The flux of autophagy was confirmed by the autophagic inhibitors 
concanamycin A and bafilomycin A [312]. Moreover, acridine orange (AO) staining showed 
the formation of acidic vacuolar organelles (AVOs). Our findings show that hyperthermia 
increased the level of AVOs after exposure of 4-CMC and 4-MMC. This result may have 
potential significance in some neurodegenerative diseases [313-315]. 
In conclusion, hyperthermia increases cytotoxicity and mitochondrial dysfunction of 
methcathinones. However, it also can activate cellular defense mechanism by inducing the 
expression of Hsp 70 proteins. The accumulation of misfolded proteins and damaged 
organelles drastically promote autophagic death processes.  
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In conclusion, our studies demonstrate that in the amphetamine group drugs, 4-FA 
and PCA show mitochondrial toxicity in HepG2 cells, undifferentiated and differentiated 
SH-SY5Y cells, while amphetamine has potential mitochondrial toxicity in HepG2 cells. 
Moreover, high concentrations of 4-FA can trigger apoptosis in HepG2 cells, while PCA can 
induce apoptosis in undifferentiated and differentiated SH-SY5Y cells. Furthermore, we also 
found that the toxicity rank for the para-substituents: chloride >fluoride >hydrogen. 
Concerning the synthetic cathinones, α-PVP and naphyrone strongly affect 
mitochondria in C2C12 cells. The inhibition of the ETC results in downstream effects like 
ATP depletion and ROS production. Additionally, 4-CMC is a strong mitochondrial toxicant 
in HepG2 cells, undifferentiated and differentiated SH-SY5Y cells. 4-MMC is also associated 
with mitochondrial dysfunctions in undifferentiated SH-SY5Y cells. For 4-MMC and 4-CMC, 
hyperthermic conditions may increase cytotoxicity and mitochondrial impairment, resulting 
in autophagic death processes in undifferentiated SH-SY5Y cells. In contrast, 3-MMC, 
MDPV, methylone, methcathinone and 4-FMC may affect mainly glycolysis rather than 
mitochondria.  
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Pharmacological and toxicological study on NPS currently abused is highly valuable, 
and it could further support clinical research and improve the understanding of NPS-induced 
toxicity. 
We demonstrated that several amphetamines and synthetic cathinones can cause 
mitochondrial toxicity by inhibiting the mitochondrial ETC and oxidative stress. However, 
there are some NPS that can decrease the ATP content without impairing the mitochondrial 
function. The impairment on glycolysis, may be studied in more detail. Furthermore, 
investigations whether methcathinones can cause mitophagy or impair autophagic processes 
may have a high impact for a better understanding of neurodegenerative diseases. 
As we investigated the pharmacology and toxicology effect of these NPS drugs only 
in vitro, it would be interesting to do some studies of these NPS drugs in vivo. This will allow 
us to test low drug concentrations and multiple exposures to simulate the actual use of these 
NPS and evaluate the systemic effects of these drugs. Moreover, we could study ex vivo 
primary liver, muscle and neuron cells, as better models than cell lines. Finally, we could also 
use SOD2 or NRF2 knock-out mouse models to investigate the susceptibility to oxidative 
stress. 
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